| (51) International Patent Classification 6 : <br><br> C12P 21/06, C12N 1/20, 15/00, C07H 17/00 | A1 | (11) International Publication Number: **WO 99/05307** <br><br> (43) International Publication Date: 4 February 1999 (04.02.99) |
|---|---|---|

(72) Inventors; and
(75) Inventors/Applicants (for US only): GREENWALD, Iva [US/US]; Apartment 11B, 300 Riverside Drive, New York, NY 10025 (US). HUBBARD, E., Jane [US/US]; Apartment B, 5465 Sylvan Avenue, Bronx, NY 10471 (US).

(74) Agent: WHITE, John, P.; Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY 10036 (US).

(54) Title: Sel-10 AND USES THEREOF

(57) Abstract

This invention provides an isolated nucleic acid molecule which encodes a wild–type or mutated SEL–10. This invention also provides a purified wild–type SEL–10 protein or a purified mutated SEL–10 protein. This invention also provides a method for production of an antibody capable of binding to wild–type SEL–10 or mutated SEL–10 protein. This invention also provides an antibody capable of specifically binding to wild–type SEL–10 or mutated SEL–10. This invention also provides a transgenic animal comprising the isolated nucleic molecule encoding SEL–10. This invention also provides a method for identifying a compound which is capable of ameliorating Alzheimer's disease. This invention also provides a method for determining whether a compound is capable of ameliorating Alzheimer's disease. This invention further provides a method for identifying a compound which is capable of treating cancer. This invention also provides a method for determining whether a compound is capable of treating cancer. This invention also provides a method for identifying a suppressor or enhancer that affects lin–12 or sel–12 activity in the same manner as sel–10. This invention also provides a method for producing suppressors of a sel–10 allele. This invenetion also provides a method for reversing the malignant phenotype of cells. This invention also provides a pharmaceutical composition effective in ameliorating Alzheimer's disease and treating cancer and methods of using such a pharmaceutical composition.

## Sel-10 AND USES THEREOF

This application is a continuation-in-part application of U.S. Serial No. 08/899,578, filed July 24, 1997, the contents of which is hereby incorporated by reference.

## BACKGROUND OF THE INVENTION

Simple model organisms such as the free-living soil
15   nematode C. elegans are experimentally tractable systems that can be used to provide insights into human development and disease. For example, genes associated with the development of cancer in humans have also been found in C. elegans. One of these human proto-oncogenes,
20   termed *TAN-1* (Ellisen et al., 1991), encodes a protein of the LIN-12/Notch family. This family was first identified by contemporaneous studies of the *lin-12* gene in C. elegans and the *Notch* gene in Drosophila. It has been established that activating TAN-1 or a similar murine
25   protein, Notch4, contributes to cancer formation. In C. elegans, activating LIN-12 affects cell fate decisions (Greenwald, e al., 1993; Greenwald and Seydoux, 1990; Struhl et al., 1993). Features common to all LIN-12/Notch proteins and their functions can be studied in C. elegans,
30   and the results can be directly applied to mammals, with particular relevance to the study of cancer.

C. elegans can similarly serve as a model for processes involved in the development of Alzheimer's disease in
35   humans. Two genes identified in linkage studies in humans encode    related    multipass    transmembrane    proteins,

-2-

presenilins 1 and 2 (PS1 and PS2). The normal role of
presenilins, and the mechanism by which mutant presenilins
cause Alzheimer's disease, are not known. Genetic studies
of the C. elegans presenilin SEL-12 (Levitan and
5    Greenwald, 1995; Levitan et al., 1996) offer a powerful
approach to understanding the normal role of presenilins.
The basic biology of presenilins and Notch proteins is
linked in both C. elegans and people: based on genetic
interactions with *lin-12*, *sel-12* has been shown to
10   facilitate *lin-12* signaling in C. elegans, and null
mutations in the mouse PS1 and Notch1 genes have similar
phenotypes (Wong et al., 1997; Shen et al., 1997).

The following is a detailed introduction to the first set
15   of experiments, in which the *sel-10* gene was identified as
a regulator of *lin-12* activity. In the first set of
experiments, genetic interactions between *sel-10* and *lin-
12* were discovered, and molecular and biochemical
experiments were performed to elucidate the nature of the
20   interaction. In a second set of experiments, interactions
between *sel-10* and *sel-12* were discovered, consistent with
the hypothesis that *sel-10* possibly regulates *sel-12*
activity.

25   Many cell-cell interactions that specify cell fate are
mediated by receptors of the LIN-12/Notch family and
ligands of the Delta/Serrate/LAG-2 (DSL) family (reviewed
Artavanis-Tsakonas et al., 1995). C. elegans affords an
opportunity to study a simple case of lateral
30   specification involving an interaction between two cells
of the hermaphrodite gonad. These cells, named Z1.ppp and
Z4.aaa, are initially equivalent in their developmental
potential:  each has an equal chance of becoming the
anchor cell (AC), a terminally differentiated cell type
35   that is necessary for vulval development, or a ventral
uterine precursor cell (VU), which contributes descendants
to the ventral uterus.    However, in any given
hermaphrodite, only one of these cells will become the AC,

-3-

while the other becomes a VU (Kimble and Hirsh, 1979).

Laser ablation studies have shown that this process of lateral specification, the AC/VU decision, depends on
5       interactions between Z1.ppp and Z4.aaa (Kimble, 1981; Seydoux and Greenwald, 1989).        Furthermore, genetic studies have indicated that *lin-12*-mediated signalling controls the AC/VU decision:   if *lin-12*  activity is inappropriately elevated, Z1.ppp and Z4.aaa become VUs,
10      while if *lin-12* activity is reduced, Z1.ppp and Z4.aaa become ACs (Greenwald et al., 1983).     Genetic mosaic analysis (Seydoux and Greenwald, 1989) and reporter gene studies (Wilkinson et al., 1994) have indicated that both Z1.ppp and Z4.aaa initially express *lin-12* and *lag-2*, but
15      that a stochastic small variation in ligand and/or receptor activity is subsequently amplified by a feedback mechanism that influences *lin-12* and *lag-2* transcription. Thus, Z1.ppp and Z4.aaa assess their relative levels of *lin-12* activity as part of the decision-making process,
20      before either cell commits to the AC or VU fates, and the feedback mechanism ensures that only one of the two cells will become an AC and the other will become a VU.

It is striking that the receptors (*lin-12/Notch* proteins),
25      ligands (DSL proteins), and at least one downstream signalling component (CBF1/Su(H)/LAG-1; see Christensen et al., 1996 and references therein) that mediate lateral specification are highly conserved in animals as distantly related as C. elegans, Drosophila, and vertebrates.
30      Furthermore, a feedback mechanism like that first described for the AC/VU decision (Seydoux and Greenwald, 1989) also exists for a Notch-mediated lateral interaction in Drosophila (Heitzler and Simpson, 1991) and seems likely to operate in Notch-mediated lateral interactions
35      in vertebrates (Austin et al., 1995; Chitnis et al., 1995; Washburn et al., 1997).  The identification of genes that influence *lin-12* activity during the AC/VU decision may reveal other conserved factors that participate in signal

-4-

transduction or regulate the activity of *lin-12/Notch* proteins.

Genetic screens based on suppression or enhancement of

5   *lin-12* mutations have identified a number of genes that influence *lin-12* activity.   Here, *sel-10* is described. It was first identified in a screen for suppressors of phenotypes associated with partial loss of *lin-12* activity (Sundaram and Greenwald, 1993).   *sel-10* acts as a

10  negative regulator of *lin-12* signalling, and SEL-10 is a member of the CDC4 family of F box/WD40 repeat containing proteins.   CDC4, the most extensively studied member of this family, is a Saccharomyces cerevisiae protein that is involved in the ubiquitin-mediated degradation of cell

15  cycle regulators (reviewed in King et al., 1996).

The similarity of SEL-10 to CDC4 prompted investigation of the possibility that SEL-10 is involved in the ubiquitin-dependent turnover of LIN-12/Notch proteins.

20  The experiments involved examining the biochemical effects of coexpressing C. elegans SEL-10 with a vertebrate LIN-12/Notch protein, Notch4.   This vertebrate *Notch* gene was originally termed *int-3*, because it was identified by mouse mammary tumor virus insertions into a cellular gene

25  (Gallahan and Callahan, 1989).   In *int-3* mutants, the viral long terminal repeat promotes expression of a truncated transcript that encodes a protein similar to the intracellular domains of LIN-12/Notch proteins (Robbins et al., 1992).   The complete sequence of the gene defined by

30  *int3* revealed that the extracellular domain of the predicted protein also has the hallmarks of LIN-12/Notch proteins, and hence the gene is now known as *Notch4* (Uyttendaele et al., 1996).   During normal development, *Notch4* expression is restricted primarily to endothelial

35  cells (Uyttendaele et al., 1996).   In *int-3* mutants, the inappropriate expression of a truncated transcript encoding the intracellular domain of Notch4 in mammary epithelia may alter stem cell fate decisions, thereby

contributing to the development of cancer. Furthermore, at least one human cancer, T cell acute lymphoblastic leukemia, has been associated with expression of a comparable truncated Notch protein (Ellisen et al., 1991), suggesting that inappropriate *Notch* activity could contribute to the development of a variety of tumors.

C. elegans SEL-10 physically interacts with murine Notch4 and causes a reduction in the steady-state levels of the murine *Notch4* intracellular domain. Results suggest that the negative regulation of LIN-12/Notch by SEL-10 is an evolutionarily conserved feature, given the striking parallels between the effect of *sel-10* activity on *lin-12* in C. elegans and the effect of SEL-10 expression on *Notch4* stability in mammalian tissue culture. Furthermore, the role of vertebrate *Notch* genes in oncogenesis suggests that vertebrate *sel-10* counterparts may behave as tumor suppressors.

## SUMMARY OF THE INVENTION

This invention provides an isolated nucleic acid molecule encoding a SEL-10.

5

This invention also provides a purified wild-type SEL-10 protein or purified wild-type SEL-10 fragment thereof or a purified mutated SEL-10 protein or purified mutated SEL-10 fragment thereof.

10

This invention also provides for a method for production of an antibody capable of binding to wild-type SEL-10 or mutated SEL-10 protein comprising a) administering an amount of the purified protein or fragment of wild-type

15    SEL-10 or mutated SEL-10 to a suitable animal effective to produce an antibody against wild-type SEL-10 or mutated SEL-10 protein in the animal; and b) testing the produced antibody for capability to bind wild-type SEL-10 or mutated SEL-10.

20

This invention also provides for a method for production of an antibody capable of binding to wild-type SEL-10 or mutated SEL-10 protein.

25    This invention further provides for an antibody capable of specifically binding to wild-type SEL-10 or mutated SEL-10.

This invention also provides a transgenic animal
30    comprising the isolated nucleic molecule encoding SEL-10.

This invention also provides a method for identifying a compound which is capable of ameliorating Alzheimer's disease.

35

This invention also provides various methods for determining whether a compound is capable of ameliorating Alzheimer's disease.

-7-

This invention further provides a method for identifying a compound which is capable of treating cancer.

This invention also provides for various methods for determining whether a compound is capable of treating cancer.

This invention further provides a method for identifying a suppressor or an enhancer that affects lin-12 or sel-12 activity in the same manner as sel-10, and the suppressor or enhancer so identified.

This invention also provides a method for producing enhancers of a sel-10 allele and the enhancer so produced.

This invention also provides a method for reversing the malignant phenotype of cells.

This invention also provides a pharmaceutical composition identified as being capable of amelioraing Alzheimer's disease. This invention also provides a pharmaceutical composition identified as being capable of treating cancer and various methods of ameliorating Alzheimer's disease or treating cancer which comprises administering the above-described pharmaceutical compositions.

## BRIEF DESCRIPTION OF FIGURES

**Figures 1A and 1B. Molecular cloning of sel-10.**
See Experimental Procedures for details of rescue assays,
plasmid constructions, and molecular analysis.   Genetic
markers used to map sel-10 are italicized, and two cosmids
that contain sel-10 sequences are shown in the box.  The
cosmid C07E11 and derivatives were tested for rescue.
pJH169 is identical to pJH166 except that it contains a
stop codon (indicated by an asterisk) in the predicted
coding sequence after codon 172.  Restriction sites are B,
BamHI; H, HindIII; S, SalI.
1A. Restriction map of sel-10.
1B. Predicted sel-10 transcription unit.

**Figures 2A-2C.   cDNA sequence and predicted protein
product of sel-10.**
Splice junctions are indicated by arrows below the DNA
sequence.   The first arrow indicates the SL1 splice
junction.  The F-Box (Kumar and Paietta, 1995, Bai et al.,
1996) is overlined and underlined and the WD40 repeats are
underlined and labelled in the Figure.  The lesions in
sel-10(ar41) and sel-10(ar28) are indicated with bold
letters in the nucleotide sequence and a bold asterisk
above the amino acid; both are G to A transitions
resulting in W to stop codon changes in the amino acid
sequence at residues 323 and 511, respectively.  The cDNA
termination codon is marked with an asterisk.  A sequence
conforming to the consensus polyadenylation signal
sequence is underlined, and sites of polyA attachment are
marked in bold.  Two independent cDNAs contained polyA
fourteen nucleotides downstream of this signal; two
alternative sites of attachment were also observed.

**Figures 3A and 3B: Comparison of the sel-10, yeast CDC4
and mouse MD6 sequences.**
Reverse contrast letters indicate amino acid identity
between two of the three sequences.   MD6 sequence

(accession number X54352) and CDC4 sequence (accession number X05625) are from Genbank.

3A. Alignment of SEL-10, CDC4, and MD6 F-Boxes.

3B. Alignment of WD40 repeats from SEL-10 and CDC4.

5

**Figures 4A and 4B: Coimmunoprecipitation of murine Notch4(int3) and C. elegans SEL-10 from transfected 293T cells.**

4A. Samples were immunoprecipitated with anti-Notch4 antibody and the Western blot was probed with anti-HA to visualize SEL-10HA (top panel) or anti-Notch4 to visualize Notch4(int3) (bottom panel).

4B. Samples were immunoprecipitated with anti-HA antibody and the Western blot was probed with anti-Notch4 (top panel) or anti-HA (bottom panel). For details see Experimental Procedures. Lane 1, mock transfected cells. Lane 2, pLNCint3 + pQNCX. Lane 3, pLNCX + pQNCsel-10HA. Lane 4, pLNCint3 + pQNCsel-10HA.

20 **Figure 5: SEL-10 lowers the steady-state level of Notch4(int3).**

Immunoblot analysis of Notch4(int3) proteins; the arrow indicates the expected mobility of Notch4(int3). Transient transfections of 293T cells were performed as described in Experimental Procedures. Lane 1, mock transfected cells (no DNA). Lane 2, pLNCint3 + pQNCX. Lane 3, pLNCint3 + pQNCsel-10.

## DETAILED DESCRIPTION OF THE INVENTION

Throughout this application, references to specific nucleotides are to nucleotides present on the coding strand of the nucleic acid. The following standard abbreviations are used throughout the specification to indicate specific nucleotides:

    C=cytosine          A=adenosine
    T=thymidine         G=guanosine

A "gene" means a nucleic acid molecule, the sequence of which includes all the information required for the normal regulated production of a particular protein, including the structural coding sequence, promoters and enhancers.

The nucleic acids or oligonucleotides of the subject invention also include nucleic acids or oligonucleotides coding for polypeptide analogs, fragments or derivatives which differ from naturally-occurring forms in terms of the identity or location of one or more amino acid residues (deletion analogs containing less than all of the residues specified for the protein, substitution analogs wherein one or more residues specified are replaced by other residues and addition analogs where in one or more amino acid residues is added to a terminal or medial portion of the polypeptides) and which share some or all properties of naturally-occurring forms. These nucleic acids or oligonucleotides include: the incorporation of codons "preferred" for expression by selected non-mammalian or mammalian hosts; the provision of sites for cleavage by restriction endonuclease enzymes; and the provision of additional initial, terminal or intermediate DNA sequences that facilitate construction of readily expressed vectors.

The nucleic acids and oligonucleotides described and claimed herein are useful for the information which they

-11-

provide concerning the amino acid sequence of the polypeptide and as products for the large scale synthesis of the polypeptide by a variety of recombinant techniques. The molecule is useful for generating new cloning and

5   expression vectors, transformed and transfected prokaryotic and eukaryotic host cells, and new and useful methods for cultured growth of such host cells capable of expression of the polypeptide and related products.

10  This invention provides for an isolated nucleic acid which encodes SEL-10. This isolated nucleic acid may be DNA or RNA, specifically cDNA, synthetic DNA or RNA, or genomic DNA. This isolated nucleic acid also encodes mutant SEL-10 or the wildtype protein. Where the isolated nucleic

15  acid encodes a mutant SEL-10, the mutation may be generated by in vitro mutagenesis. The isolated nucleic acid molecule encoding SEL-10 may have substantially the same amino acid sequence as shown in Figure 2.

20  This isolated nucleic acid may also encode a polypeptide comprising the amino acid sequence of SEL-10.

As used in this application, "SEL-10" means and includes any polypeptide having SEL-10 activity, e.g. promotion of

25  the turnover of mammalian Notch or mammalian presenilin. Thus, this term includes any such polypeptide whether naturally occurring and obtained by purification from natural sources or non-naturally occuring and obtained synthetically, e.g. by recombinant DNA procedures.

30  Moreover, the term includes any such polypeptide whether its sequence is substantially the same as, or identical to the sequence of any mammalian homolog of the human polypeptide, e.g. murine, bovine, porcine, etc. homologs. Additionally, the term includes mutants or other variants

35  of any of the foregoing which retain at least some of the enzymatic activity of nonmutants or nonvariants.

The invention also encompasses DNAs and cDNAs which encode

-12-

amino acid sequences which differ from SEL-10, but which do or do not produce phenotypic changes.

5      However, a mutant SEL-10 may not exhibit the same phenotype as the wildtype SEL-10. For example, a cell containing a mutant version of the sel-10 gene will express a protein unable to promote the degradation of mammalian Notch, or is able to better promote the degradation of mammalian Notch.

10

The nucleic acid of the subject invention also include nucleic acids that encode for polypeptide analogs, fragments or derivatives which differ from naturally-occurring forms in terms of the identity or location of

15     one or more amino acid residues (including deletion analogs containing less than all of the residues specified for the protein, substitution analogs wherein one or more residues specified are replaced by other residues and addition analogs wherein one or more amino acid residues

20     is added to a terminal or medial portion of the polypeptides) and which share some or all properties of the naturally-occuring forms.

The polypeptide of the subject invention also includes

25     analogs, fragments or derivatives which differ from naturally-occurring forms, but retain SEL-10 activity.

This invention also provides an oligonucleotide of at least 15 nucleotides capable of specifically hybridizing

30     with a unique sequence of nucleotides present within a nucleic acid which encodes a wildtype SEL-10 without hybridizing to a nucleic acid which encodes a mutant SEL-10. These oligonucleotides may be DNA or RNA. Such oligonucleotides may be used in accordance with well known

35     standard methods for known purposes, for example, to detect the presence in a sample of DNA which will hybridize thereto.

-13-

As used herein, "capable of specifically hybridizing" means wherein the oligonucleotide will selectively bind to only sequences which are unique to either nucleic acids encoding wildtype or mutant SEL-10.

5

The oligonucleotides include, but are not limited to, oligonucleotides that hybridize to mRNA encoding SEL-10 so as to prevent translation of the protein or cause RNA-mediated interference of endogenous gene expression.

10

This invention also provides a nucleic acid having a sequence complementary to the sequence of the isolated nucleic acid which encodes SEL-10.

15    This invention also provides a vector comprising an isolated nucleic acid encoding SEL-10. The isolated nucleic acid of the vectors is operatively linked to a promoter of RNA transcription which maybe, or is identical to, a bacterial, yeast, insect or mammalian promoter. The

20    vector may be a plasmid, cosmid, yeast artificial chromosome (YAC), bacteriophage or eukaryotic viral DNA. Specifically, this invention provides for a plasmid designated psel-10.8/1A .

25    This specific embodiment, psel-10.8/1A made by cleaving DNA which encodes a wildtype C. elegans SEL-10 and inserting the DNA into a plasmid. psel-10.8/1A was deposited on July 22, 1997 with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville,

30    Maryland 20852, U.S.A., under the provisions of the Budapest Treaty For The International Recognition Of The Deposit Of Microorganisms For The Purposes Of Patent Procedure. psel-10.8/1A has been accorded ATCC Accession Number 209154.

35

Further other numerous vector backbones known in the art as useful for expressing proteins may be employed. Such vectors include but are not limited to: adenovirus, simian

-14-

virus 40 (SV40), cytomegalovirus (CMV), mouse mammary tumor virus (MMTV), Moloney murine leukemia virus, murine sarcoma virus, and Rous sarcoma virus, DNA delivery systems, i.e liposomes, and expression plasmid delivery
5    systems.

This invention also provides a vector system for the production of a polypeptide which comprises the vector in a suitable host. Suitable host includes a cell which
10   includes, but is not limited to, prokaryotic or eukaryotic cells, e.g. bacterial cells (including gram positive cells), yeast cells, fungal cells, insect cells and animal cells.

15   Suitable animal cells include, but are not limited to, HeLa cells, Cos cells, CV1 cells and various primary mammalian cells.  Numerous mammalian cells may be used as hosts, including, but not limited to, the mouse fibroblast cell NIH 3T3, CHO cells, Ltk⁻ cells, etc.  Expression
20   plasmids such as that described supra may be used to transfect mammalian cells by methods well known in the art such as calcium phosphate precipitation, electroporation.

This invention also provides a method for producing a
25   polypeptide (e.g. SEL-10) which comprises growing a host vector system under suitable conditions permitting production of the polypeptide and recovering the polypeptide so produced.  Methods of recovering polypeptides produced in such host vector systems are
30   well-known in the art and typically include steps involving cell lysis, solubilization and chromatography. This invention also provides a method of obtaining a polypeptide in purified form which comprises:(a) introducing a vector, as described above, into a suitable
35   host cell; (b) culturing the resulting cell so as to produce the polypeptide; (c) recovering the polypeptide produced in step (b); and (d) purifying the polypeptide so recovered.  As discussed above the vector may include a

-15-

plasmid, cosmid, yeast artificial chromosome, bacteriophage or eukaryotic viral DNA. Also, the host cell may be a bacterial cell (including gram positive cells), yeast cell, fungal cell, insect cell or animal

5    cell. Suitable animals cells include, but are not limited to HeLa cells, Cos Cells, CV1 cells and various primary mammalian cells. Culturing methods useful for permitting transformed or transfected host cells to produce polypeptides are well known in the art as are the methods

10   for recovering polypeptides from such cells and for purifying them.

Using the aforementioned method, this invention also provides a purified wildtype SEL-10 and purified fragments

15   thereof, and a purified mutant SEL-10 and purified fragments thereof. Further, this invention also provides a polypeptide comprising the amino acid sequence of SEL-10, including, but limited to, fusion proteins having part of their amino acid sequence of the amino acid sequence of

20   SEL-10.

Further, this invention provides where the SEL-10 produced is labeled. Different types of labeling exist. The labeling may be by various means. For instance one may

25   tag the produced polypeptide with an established epitope such as myc. As discussed later in this application, such means of labeling are well known in the art. Further, one could also use other types of labels such as fluorescent, bioluminescent and metals.

30

This invention also provides a method for production of an antibody capable of binding to wild-type SEL-10 or mutated SEL-10 protein comprising: a) administering an amount of the purified protein or fragment of wild-type SEL-10 or

35   mutated SEL-10 to a suitable animal effective to produce an antibody against wild-type SEL-10 or mutated SEL-10 protein in the animal; and   b) testing the produced antibody for capability to bind wild-type SEL-10 or

-16-

mutated SEL-10.

The antibody may be produced by in vitro immunization and tested by either Western blot analysis,

5   immunoprecipitations, or staining of cells or tissue sections.

Antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules and those

10  portions of an immunoglobulin molecule that contains the paratope, including those portions known in the art as Fab, Fab', F(ab')$_2$ and F(v), which portions are preferred for use in the therapeutic methods described herein.

15  This invention also provides a method for production of an antibody capable of binding to wild-type SEL-10 or mutated SEL-10 protein comprising: a) determining conserved regions revealed by alignment of the wild-type SEL-10 or mutated SEL-10 protein sequences; b) synthesizing peptides

20  corresponding to the revealed conserved regions; c) administering an amount of the synthesized peptides to a suitable animal effective to produce an antibody against the peptides in the animal; and d) testing the produced antibody for capability to bind wild-type SEL-10 or mutant

25  SEL-10.

The antibody may be produced by in vitro immunization and tested by either Western blot analysis, immunoprecipitations, or staining of cells or tissue

30  sections.

This invention also provides an antibody capable of specifically binding to wild-type SEL-10 or mutated SEL-10, and produced by the above-described methods.  In a

35  specific embodiment, the antibody is a monoclonal antibody.  Further, the antibody may be labeled.

The labeled antibody may be a polyclonal or monoclonal

-17-

antibody. In one embodiment, the labeled antibody is a purified labeled antibody. The term "antibody" includes, by way of example, both naturally occurring and non-naturally occurring antibodies. Specifically, the term

5    "antibody" includes polyclonal and monoclonal antibodies, and fragments thereof. Furthermore, the term "antibody" includes chimeric antibodies and wholly synthetic antibodies, and fragments thereof. The detectable marker may be, for example, radioactive or fluorescent. Methods

10   of labeling antibodies are well known in the art.

This invention also provides transgenic animal comprising the isolated nucleic molecule encoding SEL-10, specifically the transgenic animal is a *Caenorhabditis*

15   *elegans*.

This invention provides a method for identifying a compound which is capable of ameliorating Alzheimer's disease comprising administering an effective amount of

20   the compound to the transgenic animal comprising the isolated nucleic acid molecule encoding SEL-10, alteration of the conditions of the transgenic animal indicating that the compound is capable of ameliorating Alzheimer's disease.

25

This invention also provides for a method for determining whether a compound is capable of ameliorating Alzheimer's disease comprising: a) treating *Caenorhabditis elegans* mutants having reduced, increased or altered sel-10

30   activity with the compound; and b) determining whether the compound suppresses, enhances or has no effect on the phenotype of the mutants, the suppression or enhancement of the phenotype indicating the compound is capable of ameliorating Alzheimer's disease. An alternative means of

35   determination is by a) contacting the compound with a cell which expresses both SEL-12 and SEL-10; and        b) determining whether the compound increases, decreases or has no effect on the amount of SEL-12 in the cell, the

-18-

increase or decrease of SEL-12 indicating that the compound is capable of ameliorating Alzheimer's disease. A third means of determination is by contacting the compound with a cell which expresses both LIN-12 and SEL-10; and determining whether the compound increases, decreases or has no effect on the amount of LIN-12 in the cell, the increase or decrease of LIN-12 indicating that the compound is capable of ameliorating Alzheimer's disease. A fourth means for determining whether a compound is capable of ameliorating Alzheimer's disease comprising: a) contacting the compound with a cell which expresses both mammalian presenilin and SEL-10; and b)determining whether the compound increases, or decreases or has no effect on the amount of mammalian presenilin in the cell, the increase or decrease of mammalian presenilin indicating that the compound is capable of ameliorating Alzheimer's disease.

As used herein "LIN-12" is a homolog of mammalian Notch protein that is found in C. elegans.

As used herein "SEL-12" is a homolog of mammalian presenilin protein that is found in C. elegans.

This invention also provides a method for identifying a compound which is capable of treating cancer comprising administering an effective amount of the compound to the transgenic animal comprising the isolated nucleic acid encoding SEL-10, alteration of the conditions of the transgenic animal indicating that the compound is capable of treating cancer.

This invention provides also a method for determining whether a compound is capable of treating cancer comprising: a) treating Caenorhabditis elegans mutants having reduced, increased or altered sel-10 activity with the compound; and b) determining whether the compound suppresses, enhances or has no effect on the phenotype of

-19-

the mutants, the suppression or enhancement of the phenotype indicating the compound is capable of treating cancer.

5    This invention also provides a method for determining whether a compound is capable of treating cancer comprising: a) contacting the compound with a cell which expresses both LIN-12 and SEL-10; and    b) determining whether the compound increases, decreases or has no effect

10   on the amount of  LIN-12 in the cell, the increase or decrease of LIN-12 indicating that the compound is capable of treating cancer.  Another means of determination is a) treating   C.   elegans   mutants   with   the   compound, b))determining whether the compound suppresses, enhances

15   or  has  no  effect  on  the  phenotype  of  mutants,  the suppression or enhancement of the phenotype indicating that the compound is capable of treating cancer. A third means of determination  whether a compound is capable of treating cancer comprises a) contacting the compound with

20   a cell which expresses both mammalian Notch and SEL-10; and    b) determining whether the compound increases, decreases or has no effect on the amount of mammalian Notch in the cell, the increase or decrease of mammalian Notch indicating that the compound is capable of treating

25   cancer.

This invention also provides a method for identifying a suppressor that affects lin-12 or sel-12 activity in the same manner as sel-10, comprising: a) mutagenizing lin-12

30   or sel-12 *Caenorhabditis elegans* worms with an effective amount  of  an  appropriate  mutagen:  b)  screening  for revertants  in  the  F1,  F2,  and  F3  generations;  and    c) isolating the screened revertants, thereby identifying a suppressor of the phenotype of lin-12 or sel-12 mutation.

35

This invention also provides for a suppressor identified by the above-described method.

-20-

This invention also provides for a method for identifying an enhancer that affects lin-12 or sel-12 activity in the same manner as sel-10, comprising: a) mutagenizing lin-12 *Caenorhabditis elegans* worms with an effective amount of an appropriate mutagen; b)screening for enhancement in the F1, F2, and F3 generations; and c) isolating the screened enhancers, thereby identifying an enhancer of the phenotype of lin-12 or sel-12 mutation.

10    This invention also provides an enhancer identified by the above-described method.

This invention also provides a method for producing suppressors of a sel-10 allele comprising: a) 15    mutagenizing sel-10 mutant hermaphrodites with an effective amount of a mutagen; b) screening for revertants in the F1, F2, and F3 generations; and c) isolating the screened revertants. This invention also provides a suppressor produced by the above-described method.

20

This invention also provides a method for identifying a suppressor gene comprising performing DNA sequence analysis of the suppressor identified by the above-described means to identify the suppressor gene, and the 25    suppressor gene so identified.

This invention also provides a method for producing enhancers of a sel-10 allele comprising: a) mutagenizing sel-10 mutant hermaphrodites with an effective amount of 30    a mutagen; b) screening for enhanced mutant in the F1, F2, and F3 generations; and c) isolating the screened enhancers. This invention also provides a enhanced mutant produced by the above-described method.

35    This invention also provides a method for identifying a enhancer gene comprising performing DNA sequence analysis of the enhancer identified by the above-described means to identify the enhancer gene, and the enhancer gene so

-21-

identified.

This invention also provides a method for reversing the malignant phenotype of cells comprising: a) linking the
5    wild-type or mutated sel-10 gene to a regulatory element such that the expression of the sel-10 gene is under the control of the regulatory element; and b) introducing the linked sel-10 gene into the malignant cells for the expression of the sel-10 gene so as to reverse the
10   malignant phenotype of cells. One could place the cells from step (b) in appropriate conditions to express the sel-10 gene such that the expression of the sel-10 gene will reverse the transforming phenotype of the malignant cells.
15

In the above-described method, one could induce the expression of the sel-10 gene which will reverse the transforming properties of the cells, thereby reversing the phenotype of the malignant cells in the subject.
20

This invention also provides for pharmaceutical compositions comprising an effective amount of the compound identified to ameliorate Alzheimer's disease and a suitable carrier.
25

This invention also provides a pharmaceutical compositions comprising an effective amount of the compound identified to treat cancer and a suitable carrier.

30   Further one could ameliorate Alzheimer's disease by administrating the above-described pharmaceutical composition in an amount effective to ameliorate Alzheimer's disease.

35   One could also treat cancer by administering the above-described pharmaceutical composition in an amount effective to treat cancer.

-22-

This invention is illustrated in the Experimental Details section which follows. These sections are set forth to aid in an understanding of the invention but are not intended to, and should not be construed to, limit in any way the invention as set forth in the claims which follow thereafter.

-23-

## EXPERIMENTAL DETAILS

## First Series Of Experiments

5    Experimental Procedures

### 1.    General methods and strains

General methods are described by Brenner (1974).   The
10   wild-type parent for all strains was C. elegans var.
Bristol strain N2.    Mapping experiments utilized the
Bristol/Bergerac congenic strain GS352, in which the
region between rol-4 and par-1 of Bristol was replaced
with the corresponding region from the Bergerac strain BO
15   (Tuck and Greenwald, 1996).   Strains were grown at 20°
unless otherwise noted.

Mutations used are described in Hodgkin (1997); additional
references for critical alleles are also given.
20   LGIII: dpy-17(e164), unc-36(e251)     andunc-32(e189)  ;
lin-12(ar170)     (Hubbard et al., 1996; E.J.A.H.,
unpublished observations); lin-12(n379) (Greenwald et al.,
1983).
LGIV: dpy-20(e1282)  .
25   LGV: nDf42 (M. Hengartner and H.R. Horvitz, personal
communication), lon-3(e2175) rol-4(sc8), sel-10(ar41)
(Sundaram and Greenwald, 1993), him-5(e1490),
unc-76(e911).

### 30   2.  Mapping of the sel-10 locus

sel-10 had been genetically mapped between lin-25 and
unc-76 V (Sundaram and Greenwald, 1993), and approximately
0.2MU to the left of him-5.   sel-10 was mapped between
35   arP3 and TCPAR1 by identifying Rol Him non-Unc
recombinants from heterozygotes of the genotype rol-4 BO
unc-76/lon-3 sel-10 him-5  constructed using the strain
GS352.   Fifty independent recombinants were analyzed by

Southern blot hybridization for the presence of arP3 and
TCPAR1 (see Tuck and Greenwald, 1996), and each
recombinant strain was tested for the presence of
sel-10(ar41) by crossing into lin-12(n379) and scoring for
5    the Muv phenotype.    Mapping data can be found in ACeDB
(Edgley et al. 1997).


## 3.  sel-10 cloning by anti-suppression assay


10   sel-10(ar41) partially suppresses the 2AC defect caused by
lin-12(ar170):    at 25°C, ~80% of lin-12(ar170) animals
have 2AC while ~25% of lin-12(ar170); sel-10(ar41) animals
have 2AC.    Reversal of suppression was used as the basis
of assessing sel-10(+) activity of microinjected DNAs.
15   Transgenic lines were generated by microinjecting the germ
lines    of    lin-12(ar170);    dpy-20(e1282);sel-10(ar41)
him-5(e1490)  hermaphrodites with cosmid or plasmid DNA
(Mello et al., 1991) at a concentration of 5µg/ml, along
with the dpy-20(+) transformation marker DNA at 10µg/ml
20   (plasmid pMH86; Han and Sternberg, 1991) and carrier
Bluescript DNA (Stratagene) at 90µg/ml.    Synchronous
populations were obtained by allowing groups of transgenic
hermaphrodites to lay eggs at 20°C for 1-2 hours and
tranferring the eggs to 25°C. The non-Dpy L3
25   hermaphrodites were then scored for the number of anchor
cells.  The injected tester DNA was considered to contain
sel-10(+)  sequences if >50% of the non-Dpy animals had
2AC. Typically, 60-80% 2AC was achieved in these "rescued"
lines.    Arrays scored as having sel-10(+) activity were
30   subjected to a second test, the ability to reverse the Muv
phenotype of lin-12(n379);sel-10 (ar41).   Initial rescue
was obtained with a pool of seven overlapping cosmids from
the region (each at 5µg/ml), then with the single cosmid
C07E11, and then with plasmids derived from C07E11, as
35   shown in Figure 1.


## 4.  Plasmids containing sel-10 genomic sequences

-25-

pJH151 was constructed by digesting cosmid C07E11 with
BamHI and ligating the 15kb fragment to Bluescript KS+
(Stratagene).    pJH166 was constructed by ligating an 8kb
PstI-SalI fragment from pJH151 into Bluescript KS+. The
PstI site was from the vector while the SalI site is from
the genomic sequences.   The ~9kb SalI fragment was removed
from pJH151 to form pJH165, and pJH167 was made by
ligation of the internal HindIII fragment of pJH151 into
Bluescript.   To construct pJH169, pJH166 was cut with PmeI
and a linker containing an NheI site with a stop codon in
all frames (NEB #1060) was inserted, creating a stop codon
after amino acid 172 in the SEL-10 sequence.


## 5.  sel-10 overexpression

arEx93    was    generated    by    microinjecting    dpy-20
hermaphrodites with pJH166 [sel-10(+)] at a concentration
of 100μg/ml, pMH86 [dpy-20(+)] at 10μg/ml, and Bluescript
DNA at 90μg/ml. Strains carrying this array segregate
sterile animals as well as fertile animals; the basis for
the sterility has not been established.   Many of the
fertile animals display a leaky Egl phenotype similar to
that observed in certain lin-12 hypomorphic mutants.
Similar results were observed with other lines at this
concentration and with lines established using pJH166 at
50μg/ml.


The    control    array    arEx149    was    established    by
microinjecting unc-32; dpy-20 hermaphrodites with pMH86 at
10μg/ml, and Bluescript DNA at 90μg/ml into unc-32; dpy-20
animals.


## 6.  Molecular analysis of sel-10

Standard    methods    were    used    for    the    manipulation    of
recombinant DNA (Sambrook et al., 1989).   sel-10(+) cDNAs
were obtained by screening approximately 100,000 pfu from
a phage library kindly provided by R. Barstead (Barstead
and Waterston, 1989).   Ten positive plaques were purified

-26-

by two subsequent rounds of screening using a radiolabelled fragment from pJH166 (~8 kb BamHI/SalI fragment) as a probe. cDNA 1A, the longest cDNA obtained, was sequenced in its entirety on one strand and compared

5      with genomic sequence from the genome project using GENEFINDER (see Waterston et al., 1997). The sequence of the cDNA 1A differed from the GENEFINDER prediction in the location of the junction between the second and third exons and in the predicted 3' end. Four of the cDNAs

10     were polyadenylated at their 3' ends (one 294, one 581 and the other two 601 bases after the predicted stop codon). Of these, only the last two were in the context of a conserved polyadenylation signal. The 5'-most cDNA end was located in codon 1 (cDNA 8 begins at G of the first

15     ATG), but a PCR product was amplified from DNA prepared from the same cDNA library (Barstead and Waterston, 1989; C. Dong, personal communication) contained the SL1 spliced leader at the predicted sequence 4 bases 5' of the first ATG. The 22 base SL1 sequence and a primer straddling the

20     5th and 6th exons were used for the 5' end amplification.


7.  Sequence analysis


Standard techniques were used to obtain sequence of the 1A

25     cDNA (Sambrook et al., 1989). The lesions associated with the sel-10(ar41) and sel-10(ar28) mutations were found by direct sequencing of two PCR products from single-stranded templates (Allard et al., 1991, Kaltenboeck et al., 1992), using internal primers to cover the entire region. One

30     small segment was subcloned and sequenced (from two independent reactions each), as the sequence from this region was not easily generated using the direct method.
       Sequence comparisons and alignments were obtained using Blast (Altschul et al., 1990) through the NCBI web site

35     and GCG (version 8, Devereux et al., 1984) programs.

8.  Plasmids for cell culture experiments

Plasmids used in the transient transfection experiments
were constructed in pLNCX (Miller et al., 1989) or pQNCX
5   (Qingyou Yan and J.K., unpublished observations), vectors
that drive gene expression under the control of a CMV
promoter.

pLNCint-3 contains cDNA corresponding to the Notch4 region
10  expressed in the int3 insertion, beginning at amino acid
1411.    The Notch4(int3) protein includes the entire
intracellular domain of Notch4 and additional sequences
(see Uyttendaele et al., 1996).

15  pQNCsel-10HA   (pJH184)   encodes   a   protein   with   a
methionine-containing hemagglutinin epitope from pACT2
(Durfee et al., 1993) fused in frame (along with a short
stretch of polylinker) to cDNA 1A at amino acid 13.

20  pQNCsel-10 contains a cDNA beginning at position +3, and
encodes a protein that is probably slightly truncated at
the amino terminus, most likely beginning translation at
the methionine codon 9 (+27).    The normal termination
codon is present.
25

9.  Transfection and Western Blot Analysis

293T cells were maintained in DMEM with 10% fetal bovine
serum (FBS).    A confluent plate of cells was split 1:3 the
30  day prior to transfection.    For one 60 mm plate of cells,
4 $\mu$g of each plasmid DNA was transfected using the calcium
phosphate precipitation method.   The total amount of DNA
was kept constant by supplementation with vector DNA.

35  Two days after transfection, cells were harvested and
lysed in TENT buffer (50mM Tris•Cl (pH8.0), 2 mM EDTA, 150
mM NaCl, 1% Triton-X 100) containing protease inhibitors
(2 $\mu$g/ml aprotinin, 2 $\mu$g/ml leupeptin, 2 $\mu$g/ml pepstatin,

0.5mM PMSF). Lysates were clarified by centrifugation at 10,000g for 10 min. and protein content was determined using the BioRad Protein determination kit. Lysates containing 60μg protein were electrophoresed on 10%

5 SDS-polyacrylamide gel and transferred onto nitrocellulose membrane. The blot was blocked overnight at 4°C with TBST(10mM Tris, pH 8.0, 150mM NaCl, 0.2% Tween 20) containing 1% Bovine serum albumin (TBST-BSA). The blot was then incubated with 1 antibody diluted (1:2,000

10 anti-Notch4; 1:50 for 12CA5) in TBST-BSA for 1 hour, washed three times for 5 minutes each with TBST, the blot was incubated with secondary antibody in TBST-BSA for 1 hour. After three washes, the signal was visualized by chemiluminescence (Amersham, ECL).

15

The anti-Notch4 antiserum (G.W. and J.K., unpublished observations) is directed against the C-terminal region of Notch4 (residues 1788-1964) (Uyttendaele et al., 1996). 12CA5 anti-HA antibody was obtained from Berkeley Antibody

20 Co., Richmond, CA.


10. Immunoprecipitation


Subconfluent 60-mm dishes of 293T cells were

25 calcium-phosphate transfected with 8 mg of plasmid. Two days post-transfection, cell extracts were prepared by Triton X-100 lysis, as described above, and normalized for protein content. Extracts were precleared with sepharose CL-4B beads, incubated with antibodies (3μl of anti-Notch4

30 antiserum or 50μl of 9E10 supernatant) for six hours at 4_C, then incubated with 40μl of 50% slurry of protein A-sepharose for 1 hour at 4°C. The protein A-sepharose beads were washed with TENT buffer three times by vortexing for 10 minutes, beads were boiled in 30μl 1X

35 protein loading buffer, and then electrophoresed on a 10% SDS-polyacrylamide gel and subjected to immunoblot analysis, as described above.

-29-

## RESULTS

Mutations that influence *lin-12* activity in C. elegans may identify conserved factors that regulate the activity of *lin-12/Notch* proteins. We describe genetic evidence indicating that *sel-10* is a negative regulator of *lin-12/Notch* mediated signalling in C. elegans are described. Sequence analysis shows that SEL-10 is a member of the CDC4 family. Biochemical data indicate that C. elegans SEL-10 physically interacts with LIN-12 and with murine Notch4, and that SEL-10 promotes LIN-12 and Notch4 degradation in mammalian cells. The parallel results obtained in C. elegans and mammalian cells suggest that negative regulation of *lin-12/Notch* activity by *sel-10* is evolutionarily conserved. We discuss potential roles are discussed for the regulation of *lin-12/Notch* activity by *sel-10* in cell fate decisions and tumorigenesis.

## 1.  Lowering sel-10 dosage elevates lin-12 activity

Two *sel-10* alleles, *sel-10(ar28)* and *sel-10(ar41)*, were identified in a screen for suppressors of defects caused by a partial loss-of-function allele of *lin-12* (Sundaram and Greenwald, 1993). These *sel-10* alleles were shown to suppress multiple defects associated with loss of *lin-12* activity, and to enhance defects associated with elevated *lin-12* activity (Sundaram and Greenwald, 1993). Here, evidence is provided that shows that *sel-10* alleles reduce *sel-10* activity, indicating that *sel-10* is a negative regulator of *lin-12* activity.

For the genetic analysis of sel-10, genetic interactions with mutations in lin-12 were relied upon. Two lin-12-mediated decisions were studied (reviewed in Greenwald, 1997). One decision is made by two cells of the hermaphrodite gonad, Z1.ppp and Z4.aaa, between the anchor cell (AC) and ventral uterine precursor cell (VU)

-30-

fates; normally, only one of these two cells becomes the AC, while the other becomes a VU (see Introduction). Eliminating lin-12 activity causes both Z1.ppp and Z4.aaa to become ACs (the "2 AC defect"), and constitutively

5    activating LIN-12 causes both Z1.ppp and Z4.aaa to become VUs.   The other decision is made by the six vulval precursor cells, between a particular vulval fate termed "2°" or an alternative fate; normally, two of the six vulval precursor cells, P5.p and P7.p, adopt the 2° fate.

10   Eliminating lin-12 activity causes all six vulval precursor cells to adopt alternative non-2° fates, and constitutively activating LIN-12 causes all six vulval precursor cells to adopt the 2° fate.   Thus, mutants in which LIN-12 is constitutively active display a "0 AC

15   Egg-laying (Egl) defect" because the absence of an AC prevents normal vulval formation; they are also Multivulva (Muv), because the descendants of each vulval precursor cell that adopts the 2° fate forms a pseudovulva.


20   To investigate the nature of the sel-10(ar41) allele, gene-dosage   studies   were   performed   assessing   the enhancement of lin-12(n379), a weakly activated lin-12 allele   in   different   sel-10   genetic   backgrounds. lin-12(n379) homozygotes display the 0 AC-Egl defect, but

25   do not have the Muv defect characteristic of strongly activated lin-12 alleles (Table 1, line 4).   However, double   mutants   display   a   highly   penetrant   0   AC-Egl phenotype and furthermore are Muv (Table 1, lines 1 and 2 and 4 and 7), suggesting that lin-12 activity is elevated

30   by the sel-10(ar41) mutation.


Table 1.
sel-10  gene dosage analysis.


35   | Relevant genotype | %Egl (n) | %Muv (n) | %Ste/Let (n) |
|---|---|---|---|
| 20° | | | |
| lin-12(d)/+[a] | 6 (93) | 0 (93) | 0 (93) |
| lin-12(d)/+;sel-10[b] | 91 (54) | 0 (54) | 0 (54) |

-31-

*lin-12(d)/+;sel-10/Df^c*    92 (39)    15 (39)    0 (39)


15·

*lin-12(d); +^d*              86 (60)    0 (60)     0 (60)
5   *lin-12(d);sel-10/+^e*      98 (62)    0 (62)     0 (62)
*lin-12(d);+/Df^f*            89 (57)^i   62 (74)    10 (63)
*lin-12(d);sel-10^g*         100 (70)^i   78 (197)   55 (126)
*lin-12(d);sel-10/Df^h*       —          85 (34)    100 (34)^j


10  Complete genotypes are:

    (a)  *lin-12(n379)/unc-36(e251); lon-3(e2175)/him-5(e1490)*

    (b)  *lin-12(n379)/unc-36(e251); lon-3(e2175) sel-10(ar41)*

    (c) *lin-12(n379)/unc-36(e251);lon-3(e2175)*
    *sel-10(ar41)/nDf42*

15  (d)  *lin-12(n379); lon-3(e2175)/him-5(e1490)*

    (e)  *lin-12(n379); lon-3(e2175) sel-10(ar41)/him-5(e1490)*

    (f)  *lin-12(n379); lon-3(e2175) /nDf42*

    (g)  *lin-12(n379); lon-3(e2175) sel-10(ar41)*

    (h)  *lin-12(n379); lon-3(e2175) sel-10(ar41)/nDf42*

20

    Complete broods were scored by picking individual L4
    animals and inspecting the plates at 24 and 48 hours for
    the absence of eggs on the plate (Egl) and for the
    presence of three or more pseudovulvae along the ventral
25  hypodermis (Muv). Plates were then inspected after an
    additional three days for the presence of live progeny
    ("Ste/Let" refers to absence of live progeny and was, in
    this case, a combination of sterility (Ste) and embryonic
    lethality(Let)). In some cases, broods were scored in
30  batch for the Muv phenotype.
    [i]Percent of fertile animals displaying the Egl defect.
    [j]Inferred genotype: Complete broods from
    *lin-12(n379)/unc-36(e251);lon-3(e2175) sel-10(ar41)/nDf42*
    were scored. The percentage of sterile non-Unc, non-Lon
35  progeny (34/97 = 35%) is approximately equal to that
    expected for *lin-12(n379); lon-3(e2175) sel-10(ar41)/nDf42*
    genotypic class. Of the remaining 63 animals, 61/63 were
    unambiguously scored as heterozygotes in the next
    generation while the remaining 2/63 did not have a
40  sufficient number of progeny to score unambiguously.


    The enhancement of the Muv defect of lin-12(n379)/+

    hermaphrodites is more pronounced when sel-10(ar41) is

    placed in trans to the large deficiency nDf42 (Table 1,

45  lines 2 and 3). The greater enhancement seen in trans to

a deficiency may mean that the sel-10(ar41) allele is a partial loss of function allele rather than a null allele; alternatively, nDf42 may remove another gene that interacts with or is functionally redundant with sel-10.

Molecular data (see below) indicate that sel-10(ar41) would lead to a drastic truncation of the predicted SEL-10 protein, suggesting that sel-10(ar41) strongly reduces sel-10 activity.

Enhancement of the Muv defect of *lin-12(n379)* hermaphrodites was observed in *nDf42/+* hermaphrodites (Table 1, lines 4 and 6). This result suggests that the *sel-10* locus is haploinsufficient.


## 2. Elevating *sel-10* dosage lowers *lin-12* activity

The molecular cloning of *sel-10(+)* (see below) enabled examination of the effect of elevated *sel-10(+)* activity, since in general extrachromosomal arrays formed after injecting DNA at a high concentration result in higher transgene expression (Mello et al., 1991). Extrachromosomal arrays containing high-copy arrays of the *sel-10* genomic region (see below) appear to lower *lin-12* activity as assayed by their effect on the AC/VU decision. There is a dramatic decrease in the proportion of *lin-12(n379)* hermaphrodites displaying the 0 AC defect in the presence of the high copy number array *arEx93* (Table 2A). In addition, the presence of the *arEx93* array enhances the 2AC defect caused by a partial loss of *lin-12* function (Table 2B). Therefore, the level of *sel-10* activity appears to control the level of *lin-12* activity, since increasing or decreasing the activity of *sel-10* has reciprocal effects on *lin-12* activity.


**Tables 2A and 2B.**

Increased dosage of *sel-10* reduces *lin-12* activity.


2A) Suppression of phenotypes associated with increased *lin-12* activity

| Relevant genotype | %0AC (n) |
|---|---|
| *lin-12(d); dpy-20;Ex[sel-10(+) dpy-20(+)]* | 51 (47) |
| *lin-12(d); dpy-20;Ex[dpy-20(+)]* | 95 (44) |

5      2B) Enhancement of phenotypes associated with reduced
       *lin-12* activity

| Relevant genotype | %2AC (n) |
|---|---|
| *lin-12(h); dpy-20;Ex[sel-10(+) dpy-20(+)]* | 97 (34) |
| *lin-12(h); dpy-20;Ex[dpy-20(+)]* | 30 (40) |
| *lin-12(+);dpy-20(e1282);Ex[sel-10(+) dpy-20(+)]* | 0(0/87) |

Complete genotypes: *lin-12(d)=lin-12(n379)*, *lin-12(h) =
lin-12(ar170)*, *dpy-20(h) = dpy-20(e1282)*, *Ex[sel-10(+)
dpy-20(+)]=arEx93*, *Ex[dpy-20(+)]=arEx149*. (See
Experimental Procedures for details of strain
constructions). Non-Dpy animals segregating from the
strains were scored in the L3 stage for the number of
anchor cells.

3. *Sel-10* Mutants Display Low Penetrance Defects
Associated with Constitutive Activation of *Lin-12*

Most *sel-10* animals appear wild-type. About 1% of
*sel-10(ar41) him-5* hermaphrodites were observed to lack an
AC. Furthermore, about 4% of *sel-10(ar41)* males display a
gonad Migration (Mig) defect similar to that seen in
*lin-12(d)* mutants, where it results from to failure to
form the linker cell, the male counterpart of the
hermaphrodite AC (Greenwald et al., 1983). In addition,
about 8% of *sel-10* mutant hermaphrodites are Egl even
though they have an AC, and that *sel-10* males have a
reduced mating efficiency that can not be completely
accounted for by the Mig defect. These additional defects
may reflect the effect of increased *lin-12* activity on
other cell fate decisions (Greenwald et al., 1983).

4. Cell Autonomy of Sel-10 Function

Two lines of evidence suggest that *sel-10* functions cell
autonomously to elevate *lin-12* activity. First, the

-34-

effect of reducing *sel-10* activity on the activity of the intracellular domain of LIN-12 was examined. Expression of *lin-12(intra)* causes phenotypes associated with LIN-12 activation (Struhl et al., 1993). Since LIN-12(intra)

5　lacks the extracellular domain and hence is active in the absence of external signalling, an enhancement of *lin-12(intra)* activity by *sel-10* mutations would be evidence for cell autonomy of *sel-10* function. An extrachromosomal array that contains the *lin-12(intra)*

10　transgene and a transformation marker were used (see Experimental Procedures); this array results in a low-penetrance *lin-12* activated phenotype (Table 3A).

**Tables 3A and 3B.**

15　Cell autonomy of *sel-10* function.

3A) Enhancement of *lin-12*(intra)

| Relevant genotype | %Egl (n) | %Mig (n) |
|---|---|---|
| *sel-10(+);arEx[lin-12(intra)]* | 16 (88)[a] | 10 (57) |
| *sel-10(ar41);arEx[lin-12(intra)]* | 46 (136)[a] | 59 (90) |

All strains also contained *him-5(e1490)*. *arEx[lin-12(intra)]* = *arEx152* (Fitzgerald, personal

25　communication) is an extrachromosomal array formed by microinjection (Fire, 1986; Mello et al., 1991) of pRF4 (plasmid containing *rol-6(su1006)* sequence that confers a Rol phenotype onto worms carrying the array) at 100µg/ml and pLC8 (Struhl et al., 1993).

30

[a]We infer that these Egl hermaphrodites lacked an AC because we scored additional hermaphrodites of relevant genotype *sel-10; arEx[lin-12(intra)]* in the L3 stage for the presence or absence of an AC and as adults for their

35　egg-laying ability, and found that nine hermaphrodites that clearly had a single AC were non-Egl, while nine hermaphrodites that clearly lacked an AC were Egl.

3B) Cell Ablation

40

| Relevant genotype | %0AC (n) | |
|---|---|---|
| | unoperated | operated |
| *lin-12(n379)/+ ; sel-10(+)* | 10 (57) | 9 (11) |
| *lin-12(n379)/+; sel-10(ar41)* | 97 (71) | 83 (12) |

-35-

Complete genotype: *dpy-17(e164) lin-12(n379)/unc-32(e189);*
*lon-3(e2175) sel-10(+ or ar41)*

"Operated" refers to worms in which Z4 was laser ablated
in the early L1 stage (when the gonad primordium consisted
of four cells, Z1-Z4). Worms were then scored in the L3
stage for the presence or absence of an AC.

When this array is combined with *sel-10(ar41)*, there is a
dramatic increase in the proportion of hermaphrodites
displaying the OAC-Egl defect and males displaying the Mig
defect (Table 3A), suggesting that *sel-10 (+)* activity
normally reduces lin-12 function in the same cell.

*sel-10* functions were tested in the receiving end of
*lin-12*-mediated cell-cell interactions by performing cell
ablation experiments to remove the signalling cell, in
this case Z4.aaa (Table 3B). This experiment enables
different genotypes to be compared with respect to their
intrinsic level of constitutive *lin-12* activity in Z1.ppp.
    If Z4, the precursor to Z4.aaa, is ablated in
*lin-12(n379)/+* hermaphrodites, Z1.ppp usually becomes an
AC, because the level of constitutive *lin-12* activity is
relatively low. However, if Z4 is ablated in
*lin-12(n379)/+; sel-10* hermaphrodites, Z1.ppp usually
becomes a VU, suggesting that the level of constitutive
*lin-12* activity is relatively high. These results
suggest that *sel-10 (+)* functions to reduce *lin-12*
activity cell autonomously, since a high level of
intrinsic *lin-12* activity is seen when *sel-10* activity is
reduced even when the signalling cell is removed.

5. Cloning of Sel-10 by an Anti-Suppression Assay

*sel-10* was previously mapped to an interval between *lin-25*
and *unc-76* on LGV(Sundaram and Greenwald, 1993). The map
position to a 300 kb interval between the cloned
polymorphisms *arP3* and *TCPAR1* space were refined (see
Experimental Procedures and Fig. 1). Cosmids from the
region were tested for their ability to reverse the

-36-

suppression of the 2AC defect of *lin-12(ar170)* by *sel-10(ar41)* (see Experimental Procedures). The cosmid C07E11 gave rescue in this anti-suppression assay and also reversed the enhancement of *lin-12(n379)* by *sel-10(ar41)*.

5   This cosmid was further subcloned and the ~8kb fragment in pJH166 gave results similar to that seen with the entire cosmid (Figure 1).


6.  Molecular Analysis of *Sel-10*

10

The ends of pJH166 (Figure 1) were sequenced and compared with sequence generated by the C.elegans genome sequencing project (Waterson et al., 1997). The entire region was found on the cosmid F55B12. A fragment from the predicted

15   open reading frame (genefinder) was radiolabeled and used to screen a Northern blot and to probe a cDNA library (see Experimental Procedures). Northern analysis revealed a single band of ~2.5kb which is present in total RNA prepared from wild type, *sel-10(ar41)* and *sel-10(ar28)*

20   strains. The ends of ten cDNAs were sequenced and the largest cDNA was sequenced in its entirety on one strand. Verification of the 5' end was obtained by sequencing products amplified from the cDNA library using the trans spliced leader sequence SL1 (Krause and Hirsh, 1987) and

25   a *sel-10*-specific sequence for primers. The splice junction of SL1 to the *sel-10* coding region occurs four bases upstream of the first predicted start codon. Figure 2 summarizes the results of the sequence analysis of sel-10.

30

7.  Sel-10 Encodes a Protein of the Cdc4 Family of Proteins


A BLAST search (Altschul et al., 1990) using the predicted

35   SEL-10 protein sequence revealed that it contains two previously identified amino acid sequence motifs (Figure 3). There are seven tandem WD40 repeats, also known as βtransducin repeats, a conserved repeat of approximately

40 amino acids named for the common appearance of Trp-Asp (WD) at the end of the repeat (reviewed in Neer et al., 1994). The crystal structure of βtransducin reveals that the seven repeats form a β propeller structure, which most

5    likely mediates protein-protein interactions (Gaudet et al., 1996; Lambright et al., 1996; Sondek et al., 1996). There is a great deal of functional diversity among WD40 repeat-containing proteins.

10   There is another motif (Kumar and Paitta, 1995) that is now called the F-Box, after its occurrence in cyclin F (Bai et al. 1996). The F-Box motif has also been implicated in protein-protein interactions, and is found in a large variety of proteins, many of which contain

15   other recognizable motifs C-terminal to the F-Box (Bai et al., 1996).

The presence of an F box N-terminal to a set of seven WD40 motifs is the hallmark of the CDC4 family of WD40-repeat

20   containing proteins, so SEL-10 appears to belong to this family. Furthermore, separate BLAST searches with just the SEL-10 WD40 repeats or the SEL-10 F box always identified members of the CDC4 family as the most similar. The alignment of the WD40 repeats of SEL-10 and CDC4 (Fig.

25   3B) reveals that a given WD40 repeat is more similar between yeast and worms than are the repeats within a given species. In addition, the F-Box motif present in proteins within the CDC4 subfamily is more conserved than among other F-Box-containing proteins (Figure 3A), and

30   there is more extensive homology around the F-box (Kumar and Paitta, 1995).

The CDC4 family includes proteins in fungi and vertebrates, as well as two other predicted C. elegans

35   proteins (see Discussion). The best studied member of this family, S. cerivisiae CDC4 targets Sic1 and certain G1 cyclins for degradation (reviewed in King et al., 1996). However, not all CDC4 family members are cell

cycle regulators. For example, there are proteins that negatively regulate sulfur metabolism from *S. cerevisiae*, *Neurospora crassa* and *Aspergillis nidulans* (Natorff et al., 1993; Kumar and Paietta, 1995; Thomas et al., 1995).

5     Biochemical mechanisms for other CDC4 family members have not been described.


### 8.   Sel-10 Mutations Truncate the SEL-10 Protein


10    Sequence analysis of *sel-10* mutations supports the genetic evidence suggesting that they strongly reduce *sel-10* activity. The sequence alterations caused by *sel-10(ar41)* and *sel-10(ar28)* were determined by direct sequencing of amplified genomic DNA products (see Experimental

15    Procedures). Both alleles are nonsense mutations at nucleotide positions 969 and 1533, respectively (see Fig. 2), resulting in truncated predicted proteins.


      *Sel-10(ar41)* removes the C terminal half of the protein,

20    including five of the seven WD40 repeats. This observation suggests that *sel-10(ar41)* is likely to result in a nonfunctional SEL-10 protein. It is unlikely that the two WD40 repeats that remain in this protein are functional since there are no known WD40-repeat containing

25    proteins with only two repeats (Neer et al.,1994). Furthermore, the crystal structure of β transducin reveals that the seven repeats form a β propeller structure that would not be complete in the absence of five of the seven repeats (Sondek, et al., 1996). Finally, comparable

30    mutations in another C. elegans CDC4 subfamily protein, LIN-23, behave like molecular null alleles (Kipreos, et al., submitted).


### 9.   C. elegans SEL-10 Physically Interacts with
35    LIN-12(intra) and Murine Notch4(int3)


      The observations that *sel-10* negatively regulates *lin-12* activity and resembles CDC4 suggested the possibility that

SEL-10 functions biochemically like CDC4 to promote LIN-12 turnover. This model makes two predictions. First, SEL-10 should physically interact with LIN-12/Notch proteins. Second, the steady-state level of LIN-12/Notch
5    proteins should be reduced by expression of SEL-10.

Potential interactions between SEL-10 and the intracellular domains of LIN-12/Notch proteins were probed, specifically LIN-12(intra), the intact
10    intracellular domain (see Struhl et al., 1993) and Notch4(int3), the intact intracellular domain with some additional sequences produced by the int3 mutation (Robbins et al., 1992; Uyttendaele et al., 1996). Initially the yeast two-hybrid system (Fields and Song,
15    1989) was used and preliminary results suggested that SEL-10 physically interacted with the C. elegans LIN-12 and GLP-1 intracellular domains, and the mouse Notch4(int3) intracellular domain. To examine further whether SEL-10 binds LIN-12/Notch proteins in vivo,
20    co-immunoprecipitation experiments using transfected mammalian cells were carried out (Fig. 4). 293T (Bosc) cells (human embryonic kidney cells) were transiently transfected with Notch4(int3) and/or HA-tagged SEL-10. Transfected cells were lysed and Notch4(int-3) was
25    precipitated with anti-Notch4 antibodies or, alternatively, SEL-10HA was immunoprecipitated with anti-HA antibodies. The immunoprecipitates were subjected to immunoblot analysis to identify bound proteins, and probed with anti-HA and anti-Notch4 antibodies. Under
30    both conditions, the immunoprecipitates were found to contain both Notch4(int3) and SEL-10HA. Similar results were obtained using Myc-tagged SEL-10. It was concluded that SEL-10 can be found in a complex with Notch4 in vivo.

35

Similar experiments were performed with epitope-tagged LIN-12(intra), and the coimmunoprecipitation results suggested that LIN-12 and SEL-10 also physically interact

-40-

(data not shown). However, LIN-12(intra) was poorly expressed in mammalian cells, so we proceeded with our analysis using Notch4(int3) exclusively.

5   **10. C. elegans SEL-10 Reduces the Steady State Levels of Murine Notch4(int3)**

If SEL-10 functions similarly to CDC4 in targeting specific proteins for proteolysis, then expression of
10   SEL-10 might reduce the level of LIN-12/Notch proteins. The effect of expressing SEL-10 on the steady state levels of Notch4(int3) was examined.

Transient transfection experiments in 293T cells were
15   performed, in which the steady state level of Notch4(int3) was examined in the presence or absence of SEL-10. Western blot analysis revealed that the steady state level of Notch4(int3) is reduced in cells expressing SEL-10 as compared to mock transfected cells (Fig. 5a). Three
20   independent transient transfection experiments performed in this manner yielded comparable results. A reduction in the steady state level of Notch4(int3) when epitope-tagged forms of SEL-10 were used in transient transfection experiments were also usually observed. In
25   the co-immunoprecipitation experiments described above, less Notch4(int3) precipitated from cells were consistently seen that also contained transfected SEL-10, consistent with a reduced steady-state level of Notch4(int3) protein in the presence of SEL-10 (see Fig.
30   4).

The results suggest that the biochemical mechanism by which sel-10 functions as a negative regulator of lin-12/Notch activity is by promoting LIN-12/Notch
35   degradation. Applicants were unable to look directly at whether SEL-10 promotes ubiquitination of Notch4(int3) because there is substantial polyubiquitination of Notch4(int3) even in the absence of transfected SEL-10.

-41-

The fact that the effects we see in this transfection system are relatively modest, and that ubiquitination occurs even in the absence of transfected SEL-10, may be due to the activity of an endogenous murine sel-10-like gene.

## Discussion

In this paper, genetic evidence indicates that *sel-10* is a negative regulator of *lin-12* mediated signalling in C. elegans. Mutations that lower *sel-10* activity elevate *lin-12* activity, and increasing *sel-10* dosage lowers *lin-12* activity. Furthermore, *sel-10* appears to act in the same cell as *lin-12*.

Molecular and biochemical evidence suggest that the mechanism by which *sel-10* controls *lin-12* activity is by controlling LIN-12/Notch protein levels. First, sequence analysis indicates that SEL-10 is related to the Saccharomyces cerevisiae protein CDC4, which is involved in the ubiquitin-dependent degradation of cell cycle regulators (reviewed in King et al., 1996). Second, C. elegans SEL-10 physically interacts with the intracellular domain of LIN-12 and with Notch4(int3), the intracellular domain of murine Notch4. Third, coexpression of SEL-10 with Notch4(int3) causes a reduction in the steady-state level of Notch4(int3).

The effects of *sel-10* activity on *lin-12* in C. elegans and the effect of SEL-10 expression on Notch4 stability in culture are strikingly parallel. Furthermore, C. elegans SEL-10 interacts physically with murine Notch 4, and proteins related to SEL-10 exist in mammals. These observations suggest that the negative regulation of LIN-12/Notch by SEL-10 is an evolutionarily conserved feature. Evidence suggests that SEL-10 targets LIN-12/Notch proteins for degradation. Also, potential roles for protein turnover in LIN-12/Notch-mediated cell

-42-

fate decisions were considered.


1.      SEL-10  May  Target  LIN-12/Notch  Proteins  for
Ubiquitin-Mediated Degradation

5

The attachment of ubiquitin to substrates involved a
series of protein complexes. Ubiquitin is activated by
linkage to an E1 ubiquitin activating enzyme, then
transferred to an E2 ubiquitin conjugating enzyme. Some
10  ubiquitination events also require the action of a third
complex, termed E3.   It is thought that E3 complexes may
contribute  to  substrate  specificity  (reviewed  in
Ciechanover, 1994; King et al., 1996). The Saccharomyces
cerevisiae protein Cdc4p may function in an E3 complex.
15  *CDC4* is one of a group of genes that also includes *CDC34*,
*CDC53*, and *SKP1*; together, these genes directly regulate
the level of the cyclin dependent kinase inhibitor Sic1p,
which must be destroyed for progression from G1 to S
phase.   Cdc34p is an E2 ubiquitin conjugating enzyme
20  (Goebl et al., 1988), and the current view is that Cdc4p,
Cdc53p, and Skp1p function as an E3 complex (Bai et al.,
1996; Mathias et al., 1996). Based on analysis of *sel-10*
and the data for CDC4, SEL-10 may function as part of an
E3 complex to target the intracellular domains of
25  LIN-12/Notch proteins for ubiquitin-dependent degradation.


An important issue to consider in the context of SEL-10 as
a component of an E3 complex is its specificity for
LIN-12/Notch proteins. The available C. elegans genetic
30  data  suggest  that  *sel-10*  an  allele-nonspecific,
gene-specific suppressor, supporting a role for SEL-10
specifically in regulating the activity of LIN-12, or
perhaps a small subset of proteins that includes LIN-12.
35  Allele-nonspecificity is indicated by the observation that
mutations in *sel-10* suppress/enhance all *lin-12* alleles
tested (Sundaram and Greenwald, 1993b; this work;
E.J.A.H., unpublished observations). Gene-specificity is

suggested by the fact that mutations in *sel-10* have not been identified in numerous screens in many laboratories for suppressors of other hypomorphic mutations; furthermore, suppression of various marker mutations used in routine strain constructions of hypomorphic alleles of several other genes encoding receptor proteins (E.J.A.H., unpublished observations).

The available genetic data also suggest that *sel-10* activity is not necessary for cell cycle progression, a possibility raised by the phenotype of *cdc4* mutants. Mutations in cul-1, a C. elegans gene related to S. cerevisiae CDC53, cause hyperplasia of larval blast cells, suggesting that cul-1 regulates cell-cycle progression (see Kipreos et al., 1996). No evidence that hyperplasia occurs in *sel-10(ar41)* mutants has been seen. (E.J.A.H., unpublished observations). Since *sel-10(ar41)* mutants have little or no *sel-10* activity (see Results), it is unlikely that *sel-10* is involved in cell cycle regulation per se, unless there is another functionally redundant gene that masks cell cycle involvement of *sel-10*. In contrast, mutations in another CDC4 related gene, *lin-23*, do cause hyperplasia, consistent with a role for *lin-23* in the regulation of cell cycle progression (Kipreos et al., submitted).

2. SEL-10 Mediated Degradation of LIN-12/Notch as a Mechanism for Receptor Downregulation

For a variety of cell surface receptors, ligand-induced polyubiquitination is thought to be a mechanism for down-regulation (reviewed in Ciechanover and Schwartz, 1994). It is proposed that ubiquitin-mediated degradation is also a mechanism for down-regulation of activated LIN-12/Notch proteins, and that SEL-10 plays a critical role in this process. Although no direct evidence exists for ligand-induced ubiquitination of LIN-12/Notch receptors, the free and intact intracellular domains of

LIN-12/Notch proteins have been shown to behave like activated receptors (Lieber et al., 1993; Struhl et al., 1993), and that Notch4(int3) behaves like a gain-of-function mutation (Gallahan and Callahan, 1987).

5    Biochemical data are therefore consistent with the proposal that the activated receptor may be the substrate for SEL-10-mediated polyubiquitination. For the remainder of the Discussion, possible roles of SEL-10 mediated down-regulation of LIN-12/Notch proteins in cell

10   fate decisions and oncogenesis are considered.


3.    Potential roles for SEL-10 mediated LIN-12 down-regulation in the AC/VU decision and VPC specification

15

sel-10 influences lin-12 activity in the AC/VU decision. The AC/VU decision can be considered to involve three phases prior to the committed state (Seydoux and Greenwald, 1989; Wilkinson et al., 1994). Initially,

20   Z1.ppp and Z4.aaa have equal signalling and receiving potentials; ligand (LAG-2) and receptor (LIN-12) may interact, but signalling activity is below a critical threshold. A small stochastic difference between the two cells, such that one cell has a greater level of

25   signalling activity and the other has a greater level of receiving activity, is amplified by a feedback mechanism that involves differential transcription of ligand and receptor genes. This feedback mechanism amplifies the stochastic difference that has arisen between the two

30   cells and ensures that the cell in which *lin-12* activity is greater becomes the VU while the cell in which *lin-12* activity is less becomes the AC.


The ultimate consequences of LIN-12 activation must be on

35   gene expression. For the feedback mechanism, this effect has been visualized for the transcription of *lag-2* and *lin-12*: activation of LIN-12 appears to repress transcription of *lag-2* and stimulate transcription of

*lin-12* (Wilkinson et al., 1994). At a minimum, downstream genes needed for differentiation as a VU must be activated; it is also likely that genes involved in the differentiation of an AC are repressed. *sel-10* might influence the AC/VU decision because, unless LIN-12 is down-regulated, the initial signalling that occurs between Z1.ppp and Z4.aaa might cause both cells to achieve the threshold value of effector activity.

Most *sel-10(ar41)* individuals are phenotypically wild-type, with only a small proportion displaying phenotypes associated with LIN-12 activation, may be explained in this context if there is a redundant gene product or regulatory mechanism. There is at least one additional CDC4 related gene in the C. elegans genome (E.J.A.H., unpublished observations). Furthermore, there may be other mechanisms for degrading activated LIN-12. For example, *sel-1*, another negative regulator of *lin-12* activity, may also be involved in LIN-12 turnover (see Grant and Greenwald, 1997), but since SEL-1 is a secreted or extracytosolic membrane-associated protein found in intracellular vesicles, it is not likely to be directly involved in the ubiquitination of the intracellular domain of LIN-12.

4.    Potential Roles for Degradation of Activated LIN-12/Notch Proteins in Other Cell Fate Decisions

In other cell fate decisions, including specification of the vulval precursor cells (VPCs), the role of sel-10 in the VPC decions may be similar to its role in the AC/VU decision: to ensure that a threshold value of LIN-12 activation must be reached in the appropriate cells for commitment. However, regulated turnover of activated receptors may play different or additional roles in other LIN-12/Notch mediated decisions. For example, in Drosophila eye development, *Notch* appears to be utilized for sequential cell fate decisions (Cagan and Ready,

1989), which would seem to necessitate clearance of
activated *Notch* after each decision so that a new
assessment of *Notch* activity can be made. Furthermore,
it is also conceivable that for some LIN-12/Notch mediated
5    decisions, the cell fate adopted may depend on the
intensity of signal, as has been seen for receptors for
gradient morphogens (e.g., Nellen et al., 1996). If any
LIN-12/Notch-mediated decisions do display such dosage
sensitivity, it is likely that they would depend on rapid
10   turnover of activated receptor complexes so that the
correct threshold value is read.


5.   Potential Roles for *sel-10* in Oncogenesis


15   When the intact intracellular domain of LIN-12/Notch
proteins is expressed, cell fate transformations known to
be associated with activation of LIN-12/Notch proteins are
seen, indicating that the intact intracellular domain
behaves like a constitutively active receptor (Lieber et
20   al., 1993; Struhl et al., 1993). Thus, the observation
that mammalian tumors can be induced by expression of
truncated forms of Notch largely consisting of the intact
intracellular domain (Ellisen et al., 1991; Robbins et
al., 1992; Uyttendaele et al., 1996) suggests that
25   constitutive *Notch* activity can be a causal factor in
tumor formation. Since SEL-10 downregulates *Notch*
activity, it may act to restrain the either normal or
oncogenic functions of activated *Notch*, and hence suppress
cell growth. If so, then loss-of-function mutations in
30   vertebrate *sel-10* could contribute to tumor formation by
elevating the level of *Notch* protein. For instance, human
T acute lymphoblastic leukemias, which in the majority of
cases do not contain oncogenic *Notch* alterations (Drexler
et al., 1995), and human breast tumors, which thus far
35   have not been reported to contain oncogenic *Notch*
alterations, may carry mutations in other proteins that
influence Notch activity, such as *sel-10* homologs.

Second Series of Experiments
1. Genetic Interaction Between *sel-10* and *sel-12*

5    *sel-12(ar171)* and *sel-12(ar131)* cause an egg-laying
defective (Egl) phenotype. *sel-10(ar41)* suppresses the
Egl defect of *sel-12* mutants (Table 4).

Table 4. All strains also contained the markers
10   him-5(e1490), and unc-1(e538).

| Relevant genotype | #Egl+/total | (%) |
|---|---|---|
| *sel-10(+); sel-12(ar131)* | 2/99 | (2%) |
| *sel-10(ar41); sel-12(ar131)* | 88/118 | (75%) |
| *sel-10(+); sel-12(ar171)* | 0/107 | (0%) |
| *sel-10(ar41) sel-12(ar171)* | 25/126 | (20%) |

2. Potential physical interaction between SEL-10 and
20   SEL-12, and SEL-10 and human presenilin 1 (PS1)

The genetic interaction between *sel-10* and *sel-12* raises
the possibility that there is a direct physical
interaction between the SEL-10 and SEL-12 proteins that
25   promotes the ubiquitin-mediated turnover of SEL-12
presenilin. Experiments similar to those described in the
first series of experiments, substituting SEL-12 in place
of LIN-12, can be performed. Specifically,
co-immunoprecipitation of epitope-tagged forms of SEL-10
30   and SEL-12, can be performed lowering of steady-state
levels of SEL-12 in the presence of SEL-10, and
ubiquitination of SEL-12 in the presence of SEL-10 will be
observed. Similar experiments with human PS1, other human
presenilins (e.g. PS2) and other C. elegans presenilins
35   (HOP-1) can be performed. The genetic interactions of
SEL-10 and other C. elegans presenilins will also be
performed.

3. Implications for Alzheimer's disease

If there is a physical interaction between SEL-10 and
SEL-12, such that SEL-10 promotes the ubiquitin-mediated
5   degradation of SEL-12, then compounds that interfere with
this process will be potential drugs for Alzheimer's
disease.

If there is no direct physical interaction between SEL-10
10  and SEL-12, then the suppression of *sel-12* mutations by
*sel-10* mutations is indirect, perhaps through effects on
LIN-12.  However, given the intimate connection between
LIN-12/Notch and SEL-12/presenilin in C. elegans (Levitan
and Greenwald, 1995) and mice (Wong et al., 1997; Shen et
15  al., 1997), then compounds that interfere with the
degradation of LIN-12 will be potential drugs for
Alzheimer's disease.

4. *sel-10* as a starting point for screens for other
20  potential targets

A)   Yeast two-hybrid screen for proteins that interact
     with SEL-10.

25  The two-hybrid screen, originally developed by Fields and
Song (1989), is a powerful strategy for identifying
potential interacting proteins.  The screen relies on the
ability of GAL4 to activate transcription of a reporter
gene containing GAL4 upstream activation sequences.  GAL
30  4 has a DNA binding domain (GBD) and a activation domain
(GAD).  Normally, the two domains are present in the same
polypeptide; if they are separated, GAL4 activity is
abolished.  However, if the separated domains are joined
to protein sequences that interact with each other, the
35  two domains are brought together, and GAL4 activity is
restored.  Thus, a yeast strain containing a "bait" fused
to the GBD is transformed with a library containing
potential GAD fusions, and a selection or screen for

reconstituted GAL4 activity is used to identify candidates.

This method to identify genes that interact with *lin-12* (Hubbard et al., 1996) has been used. A similar approach to identifying genes that interact with *sel-10* will be used. A bait containing sequences from SEL-10 fused to GBD has been prepared, and a derivative of yeast strain Y153 with this plasmid will be prepared. Y153 contains GAL4 UAS--HIS3 and GAL 4 UAS--lacZ, enabling candidates to be selected by the ability to grow on medium containing 3AT (HIS+ selection) or screened for beta-galactosidase activity (Durfee et al., 1993). Clones of the excellent random oligomer-primed library prepared by Bob Barstead by transforming the yeast strain Y153 and selecting for growth on 3AT plates will be screened; these transformants for beta-galactosidase activity will be screened in a filter assay. Then, from each candidate, the candidate worm-GAD plasmid will be isolated and retested with the bait (SEL-10-GBD), and with SNF1-GBD and/or lamin-GBD to check for general stickiness.

Any candidates that specifically bind SEL-10-GBD will be isolated and sequenced. The sequence analysis and derived map position (using the genome project database) may help illuminate their functions. To see if the physical interaction is functionally relevant in vivo, C. elegans mutants will be created by RNA interference or gene-knockout strategies using established methods. The candidate mutants for phenotypes and for genetic interactions with existing *sel-12*, *sel-10*, and *lin-12* mutants will then be examined.

B) Genetic screens for mutations that interact with *sel-10* will be conducted, specifically looking for extragenic suppressors or enhancers.

Screens that may be used are:

-50-

1) Mutagenizing appropriate strains so as to generate hermaphrodites of relevant genotype *lin-12(n379); sel-10/Df(sel-10);* * [where * represents a mutagenized chromosome] and look for fertile hermaphrodites. These individuals may carry extragenic suppressors that define new components of the *sel-10* pathway or complex. Genetic and molecular characterization of extragenic suppressors of *sel-10*, including their interaction with mutations in *sel-12* and *lin-12*, may identify other potential targets for drugs against Alzheimer's disease and cancer, other potential tumor suppressors or oncogenes that act in the *lin-12* pathway, and other potential genes influencing the development of Alzheimer's disease.

2) Mutagenizing appropriate strains so as to generate hermaphrodites of relevant genotype *arEx93 [sel-10(+)];* * to revert the sterility defect associated with *sel-10* overexpression. Other high copy number or highly expressing arrays in place of *arEx93* may also be used. As described above, these individuals may carry extragenic suppressors that define new components of the *sel-10* pathway or complex. Genetic and molecular characterization of extragenic suppressors of *sel-10*, including their interaction with mutations in *sel-12* and *lin-12*, may identify other potential targets for drugs against Alzheimer's disease and cancer, other potential tumor suppressors or oncogenes that act in the *lin-12* pathway, and other potential genes influencing the development of Alzheimer's disease.

-51-

## Third Series of Experiments

Mutations in either of two presenilin genes (*PS1* and *PS2*)
cause Alzheimer's disease, and reducing presenilin level
5    is a potential therapeutic target for treating Alzheimer's
disease (DeStrooper, *et al.*, 1998). We have found genetic
and physical interactions between *C. elegans* SEL-10, a
member of the CDC4 family of proteins (Hubbard, *et al.*,
1997), and SEL-12, a *C. elegans* presenilin (Levitan and
10   Greenwald, 1995). We show that a loss of *sel-10* activity
can suppress the phenotype associated with reducing *sel-12*
activity and that SEL-10 can physically complex with SEL-
12. Proteins of the CDC4 family have been shown to target
proteins for ubiquitin-mediated turnover (Hoyt, 1997). The
15   functional and physical interaction between *sel-10* and
*sel-12* therefore offers an approach to understanding how
presenilin levels are normally regulated, and therefore
how they may be reduced.

20   *sel-12* mutations cause a highly penetrant egg-laying
defective (Egl) phenotype (Levitan & Greenwald, 1995).
SEL-12 is 50% identical to human PS1 and PS2 and appears
to be a bona fide presenilin, since either human PS1 or
PS2 can efficiently substitute for SEL-12 in *C. elegans*
25   (Levitan, *et al.*, 1996). Another *C. elegans* gene, *hop-1*,
encodes a somewhat more divergent presenilin (Li &
Greenwald, 1997). In principle, loss-os-function mutations
that suppress the Egl defect of *sel-12* mutants might
augment or stabilize mutant SEL-12 proteins or HOP-1(+),
30   or bypass the need for presenilin activity.

*sel-10(ar41)* is a strong loss-of-function mutation that
dramatically suppresses the Egl defect caused by *sel-
12(ar131)* or *sel-12(ar171)* (Table 1). *sel-10(ar41)* also
35   suppresses certain cell fate transformations associated
with reducing the activity of *lin-12*, which encodes a
receptor of the LIN-12/Notch family (Hubbard, *et al.*
1997), (Sundaram & Greenwald, 1993). However, the

-52-

suppression of the *sel-12* Egl defect by reducing *sel-10* activity is unlikely to be simply an indirect consequence of the effect of *sel-10* on *lin-12* activity, since *sel-10(ar41)* efficiently suppresses *sel-12* mutations (Table 1)

5    but is unable to suppress the Egl defect caused by reducing *lin-12* activity (Hubbard, *et al.* 1997), (Sundaram & Greenwald, 1993).

If presenilins are indeed a target of SEL-10, then SEL-10

10   would be expected to associate physically with presenilins. Potential physical interactions were assessed between SEL-10 and SEL-12 by co-immunoprecipitation using transiently transfected mammalian cells. Cells were cotransfected with expression plasmids encoding myc-tagged

15   SEL-10 and HA-tagged SEL-12. Transfected cells were lysed and cell lysates were precipitated with either anti-myc antibodies or anti-HA antibodies. The anti-myc immunoprecipitate was found to contain both SEL-10myc and SEL-12HA. This result suggests that SEL-10 and SEL-12

20   presenilin are able to form a complex.

Database analysis reveals that proteins that are highly related to SEL-10 exist in mammals (Hubbard, *et al.*, 1997). The functional and physical interactions between

25   SEL-10 and SEL-12 raise the intriguing possibility that SEL-10 is part of a mechanism that regulates presenilin level or activity in mammals. Manipulation of *sel-10* activity, as well as knowledge from further studies of the nature of *sel-10* interaction with *sel-12*, may lead to

30   therapeutic strategies for ameliorating Alzheimer's disease.

-53-

Table 1. Reducing *sel-10* activity suppresses the egg-laying defect (Egl) of *sel-12* mutants. All strains also contained the markers *him-5(e1467)* and *unc-1(e538)* to facilitate genetic manipulations.

Relevant Genotype                    #non-Egl/total(%)

| *sel-10(+);sel-12(ar131)* | 2/99 (2%) |
|---|---|
| *sel-10(ar41);sel-12(ar-131)* | 88/118 (75%) |
| *sel-10(+);sel-(12ar171)* | 0/107 (0%) |
| *sel-10(ar41);sel-12(ar171)* | 25/126(20%) |

## REFERENCES

1.  Altschul, S.F., W. Gish, W. Miller, E.W. Meyers, and D.J. Lipman (1990). Basic local alignment search tool. J. Mol. Biol. 215, 403-410.

2.  Aroian, R.V., M. Koga, J.E. Mendel, Y. Ohshima, and P.W. Sternberg (1990). The let-23 gene necessary for Caenorhabditis elegans vulval induction encodes a tyrosine kinase of the EGF receptor subfamily. Nature 348, 693-9.

3.  Artavanis-Tsakonas, S., K. Matsuno, and M.E. Fortini (1995). Notch signaling. Science 268, 225-235.

4.  Bai, C., P. Sen, K. Hofmann, L. Ma, M. Goebl, J.W. Harper, and S.J. Elledge (1996). SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 86, 263-274.

5.  Barstead, R.J., and R.H. Waterston (1989). The basal component of the nematode dense-body is vinculin. J. Biol. Chem. 264, 10177-10185.

6.  Brenner, S. (1974). The genetics of Caenorhabditis elegans. Genetics 77, 71-94.

7.  Cagan, R.L., and D.F. Ready (1989). Notch is required for successive cell decisions in the developing Drosophila retina. Genes Dev. 3, 1099-1112.

8.  Chitnis, A., D. Henrique, J. Lewis, D. Ish-Horowicz, and C. Kintner (1995). Primary neurogenesis in Xenopus embryos regulated by a homolog of the Drosophila neurogenic gene Delta. Nature 375, 761-766.

-55-

9.      Christensen, S., V. Kodoyianni, M. Bosenberg, L.
        Friedman, and J. Kimble (1996).   lag-1, a gene
        required for lin-12 and glp-1 signaling in C.
        elegans, is homologous to human CBF1 and
        Drosophila Su(H).  Development 122, 1373-1383.


10.  Ciechanover, A. (1994).    The ubiquitin-proteasome
     proteolytic pathway.  Cell 79, 13-21.


11.  Ciechanover, A., and A.L. Schwartz (1994).   The
     ubiquitin-mediated proteolytic pathway: mechanisms of
     recognition of the proteolytic substrate and
     involvement in the degradation of native cellular
     proteins.  FASEB J. 8, 182-191.


12.  DeStrooper, B., et al. (1998). Nature 391, 387-380.


13.  Devereux, J., P. Haeberli, and O. Smithies (1984).  A
     comprehensive set of sequence analysis programs for
     the VAX.  Nucl. Acids Res. 12, 387-395.


14.  DeVore, D.L., H.R. Horvitz, and M.J. Stern (1995).  An
     FGF receptor signaling pathway is required for the
     normal cell migrations of the sex myoblasts in C.
     elegans hermaphrodites.  Cell 83, 611-620.


15.  Drexler, H.G.,   MacLeod, R.A.F., Borkhardt, A. and
     Janssen, J.W.G.    (1995). Recurrent chromosomal
     translocations and fusion genes in leukemia-lymphoma
     cell lines.  Leukemia 9,   480-500.


16.  Durfee, T., Becherer, K., Chen, P.-L., Yeh, S.-H.,
     Kilburn, A.E., Lee, W.-H. and Elledge, S.J. (1993) The
     retinoblastoma protein associates with the protein
     phosphatase type 1 catalytic subunit.  Genes Dev. 7,
     1-12.


17.  Edgley, M.L., Turner, C.A., and Riddle, D.L. (1997)

-56-

On-line C. elegans resources. In C. elegans II, D. L. Riddle, T. Blumenthal, B. J. Meyer and J. R. Priess, eds. (Cold Spring Harbor Laboratory Press), 1059-1062.

18. Ellisen, L.W., J. Bird, D.C. West, A.L. Soreng, T.C. Reynolds, S.D. Smith, and J. Sklar (1991). TAN-1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66, 649-661.

19. Fields, S., and O.-k. Song (1989). A novel genetic system to detect protein-protein interactions. Nature 340, 245-246.

20. Gallahan, D., and R. Callahan (1987). Mammary tumorigenesis in feral mice: identification of a new int locus in mouse mammary tumor virus (Czech II)-induced mammary tumors. J. Virol. 61, 66-74.

21. Gaudet, R., A. Bohm, and P.B. Sigler (1996). Crystal structure at 2.4 A resolution of the complex of transducin bg and its regulator, phosducin. Cell 87, 577-568.

22. Grant, B., and I. Greenwald (1997). Structure, function and expression of SEL-1, a negative regulator of LIN-12 and GLP-1 in C. elegans. Development 124, 637-644.

23. Greenwald, I. (1997). Development of the vulva. In C. elegans II, D. L. Riddle, T. Blumenthal, B. J. Meyer and J. R. Priess, eds. (Cold Spring Harbor Laboratory Press), 519-542.

24. Greenwald, I., and G. Seydoux (1990). Analysis of gain-of-function mutations of the lin-12 gene of Caenorhabditis elegans. Nature 346, 197-9.

25. Greenwald, I.S., P.W. Sternberg, and H.R. Horvitz (1983). The lin-12 locus specifies cell fates in Caenorhabditis elegans. Cell 34, 435-444.

26. Han, M., and P.W. Sternberg (1991). Analysis of dominant-negative mutations of the Caenorhabditis elegans let-60 ras gene. Genes & Dev. 5, 2188-98.

27. Heitzler, P., and P. Simpson (1991). The choice of cell fate in the epidermis of Drosophila. Cell 64, 1083-1092.

28. Hodgkin, J. (1997) Genetics. In C. elegans II, D. L. Riddle, T. Blumenthal, B. J. Meyer and J. R. Priess, eds. (Cold Spring Harbor Laboratory Press), 881-1047.

29. Hoyt, M.A. (1997). Cell 91, 149-151.

30. Hubbard, E.J.A., Dong, Q., and Greenwald, I. (1996) Evidence for physical and functional association between EMB-5 and LIN-12 in Caenorhabditis elegans. Science 273, 112-115.

31. Hubbard, E.J.A., Wu, G., Kitajewski, J.K.& Greenwald, I. (1997) Genes Dev. 11, 3182-3193.

32. Kimble, J. (1981). Alteration in cell lineage following laser ablation of cells in the somatic gonad of Caenorhabditis elegans. Dev. Biol. 87, 286-300.

33. Kimble, J., and D. Hirsh (1979). The post-embryonic cell lineages of the hermaphrodites and male gonads in Caenorhabditis elegans. Dev. Biol. 87, 396-417.

34. King, R.W., R.J. Deshaies, J.-M. Peteres, and M.W. Kirschner (1996). How proteolysis drives the cell cycle. Science 274, 1652-1658.

35. Kipreos, E.T., L.E. Lander, J.P. Wing, W.W. He, and E.M. Hedgecock (1996). cul-1 is required for cell cycle exit in C. elegans and identifies a novel gene family. Cell 85, 829-839.

36. Krause, M. and D. Hirsh (1987). A trans-spliced leader sequence on actin mRNA in C. elegans. Cell 49, 753-761.

37. Kumar, A., and J.V. Paietta (1995). The sulfur controller-2 negative regulatory gene of Neurospora crassa encodes a protein with beta-transducin repeats. Proc. Natl. Acad. Sci. (USA) 92, 3343-3347.

38. Lambright, D.G., J. Sondek, A. Bohm, N.P. Skiba, H.E. Hamm, and P.B. Sigler (1996). The 2.0 A crystal structure of a heterotrimeric G protein. Nature 379, 311-319.

39. Levitan, D., et al. (1996). Proc. Natl. Acad. Sci. (USA) 93, 14940-14944.

40. Levitan, D. & Greenwald, I. (1995). Nature 377, 351-354.

41. Li, X. & Greenwald, I. (1997). Proc. Natl. Acad. Sci. (USA) 94, 12204-12209.

42. Lieber, T., S. Kidd, E. Alcamo, V. Corbin, and M.W. Young (1993). Antineurogenic phenotypes induced by truncated Notch proteins indicate a role in signal transduction and may point to a novel function for Notch in nuclei. Genes Dev. 7, 1949-1965.

43. Mango, S.E., E.M. Maine, and J. Kimble (1991). Carboxy-terminal truncation activates glp-1 protein to specify vulval fates in Caenorhabditis elegans.

-59-

Nature 352, 811-815.

44. Mathias, N., S.L. Johnson, M. Winey, A.E.M. Adams, L. Goetsch, J.R. Pringle, B. Byers, and M.G. Goebl (1996). Cdc53p acts in concert with Cdc4p and Cdc34p to control the G1-to-S phase transition and identifies a conserved family of proteins. Mol. Cell Biol. 16, 6634-6643.

45. Mello, C.C., J.M. Kramer, D. Stinchcomb, and V. Ambros (1991). Efficient gene transfer in C. elegans: extrachromosomal maintenance and integration of transforming sequences. EMBO J. 10, 3959-3970.

46. Miller, A.D. and Rosman, G.J. (1989). Improved retroviral vectors for gene transfer and expression. Biotechniques 7, 980-990.

47. Natorff, R., M. Balinska, and A. Paszewski (1993). At least four regulatory genes control sulphur metabolite repression in Aspergillus nidulans. Mol. Gen. Genet. 238, 185-192.

48. Neer, E.J., C.J. Schmidt, R. Nambudripad, and T.F. Smith (1994). The ancient regulatory-protein family of WD-repeat proteins. Nature 371, 297-300.

49. Nellen, D., R. Burke, G. Struhl, and K. Basler (1996). Direct and long range action of a DPP morphogen gradient. Cell 85, 357-368.

50. Robbins, J., B.J. Blondel, D. Gallahan, and R. Callahan (1992). Mouse mammary tumor gene int-3: a member of the Notch gene family transforms mammary epithelial cells. J. Virol. 66, 2594-2599.

51. Rogers, S., R. Wells, and M. Rechsteiner (1986). Amino acid sequences common to rapidly degraded

proteins: the PEST hypothesis. Science 234, 364-368.

52. Seydoux, G., and I. Greenwald (1989). Cell autonomy of lin-12 function in a cell fate decision in C. elegans. Cell 57, 1237-45.

53. Shen, J., et al. (1997). Skeletel and CNS defects in presenilin-1-deficient mice. Cell 89, 629-639.

54. Sondek, J., A. Bohm, D.G. Lambright, H.E. Hamm, and P.B. Sigler (1996). Crystal structure of a GA protein bg dimer at 2.1 A resolution. Nature 379, 369-374.

55. Struhl, G., K. Fitzgerald, and I. Greenwald (1993). Intrinsic activity of the Lin-12 and Notch intracellular domains in vivo. Cell 74, 331-45.

56. Sundaram, M., and I. Greenwald (1993b). Suppressors of a lin-12 hypomorph define genes that interact with both lin-12 and glp-1 in Caenorhabditis elegans. Genetics 135, 765-783.

57. Thomas, D., L. Kuras, R. Barbey, H. Cherest, P.L. Blaiseau, and Y. Surdin-Kerjan (1995). Met30p, a yeast transcriptional inhibitor that responds to S-adenosylmethionine, is an essential protein with WD40 repeats. Mol. Cell. Biol. 15, 6526-6534.

58. Tuck, S., and I. Greenwald (1995). lin-25, a gene required for vulval induction in Caenorhabditis elegans. Genes Dev. 9, 341-357.

59. Uyttendaele, H., G. Marazzi, G. Wu, Q. Yan, D. Sassoon, and J. Kitajewski (1996). Notch4/int-3, a mammary proto-oncogene, is an endothelial cell-specific mammalian Notch gene. Development 122, 2251-2259.

60. Waterston, R.H., Sulston, J.E., and Coulson, A.R. (1997). The genome. In C. elegans II, D. L. Riddle, T. Blumenthal, B. J. Meyer and J. R. Priess, eds. (Cold Spring Harbor Laboratory Press), 23-46.

61. Wilkinson, H.A., K. Fitzgerald, and I. Greenwald (1994). Reciprocal changes in expression of the receptor lin-12 and its ligand lag-2 prior to commitment in a C. elegans cell fate decision. Cell 79, 1187-1198.

62. Wilkinson, H.A., and I. Greenwald (1995). Spatial and temporal patterns of lin-12 expression during C. elegans hermaphrodite development. Genetics 141, 513-526.

63. Wong, P.C., et al., (1997). Presenilin 1 is required for Notch1 and DII 1 expression in the paraxial mesoderm. Nature 387, 288-291.

What is claimed is:

1.   An isolated nucleic acid molecule encoding a SEL-10.

5   2.   The isolated nucleic acid molecule of claim 1, which
     encodes a mutated SEL-10.

3.   The isolated nucleic acid molecule of claim 2, wherein
     the mutation is generated by in vitro mutagenesis.

10
4.   The isolated nucleic acid molecule of claim 1, 2 or 3,
     wherein the molecule is a DNA, cDNA, genomic DNA,
     synthetic DNA or RNA.

15   5.   The isolated nucleic acid molecule of claim 1, wherein
     the encoded SEL-10 has substantially the same amino
     acid sequence as shown in Figure 2.

6.   A nucleic acid molecule of at least 15 nucleotides
20   capable of specifically hybridizing with the sequence
     of a nucleic acid molecule of claim 1.

7.   The nucleic acid molecule of claim 6, wherein the
     molecule is DNA or RNA.

25
8.   An isolated nucleic acid molecule of claim 1
     operatively linked to a promoter of RNA transcription.

9.   8A vector which comprises the isolated nucleic acid
30   molecule of claim 1.

10.  The vector of claim 9, wherein the vector is a
     plasmid.

35   11.  The plasmid of claim 10 designated psel-10.8/1A (ATCC
     Accession No. 209154).

12.  A host vector system for the production of a SEL-10

-63-

which comprises the vector of claim 9 and a suitable host.

13. The host vector system of claim 12, wherein the suitable host is a bacterial cell, insect cell, plant or animal cell.

14. The host vector system of claim 12, wherein the SEL-10 produced is labeled.

15. A purified wild-type SEL-10 protein or purified wild-type SEL-10 fragment thereof.

16. The purified wildtype SEL-10 protein or fragment thereof which is labeled.

17. A purified mutated SEL-10 protein or purified mutated SEL-10 fragment thereof.

18. The purified mutated SEL-10 protein or fragment thereof which is labeled.

19. A method for production of an antibody capable of binding to wild-type SEL-10 or mutated SEL-10 protein comprising:

    a)   administering an amount of the purified protein or fragment of wild-type SEL-10 or mutated SEL-10 to a suitable animal effective to produce an antibody against wild-type SEL-10 or mutated SEL-10 protein in the animal; and

    b)   testing the produced antibody for capability to bind wild-type SEL-10 or mutated SEL-10.

20. The method of claim 19, wherein the antibody is

-64-

produced by in vitro immunization.

21. The method of claim 19, wherein the produced antibody is tested by Western blot analysis.

22. The method of claim 19, wherein the produced antibody is tested by immunoprecipitation.

23. The method of claim 19, wherein the produced antibody is tested by staining of cells or tissue sections.

24. A method for production of an antibody capable of binding to wild-type SEL-10 or mutated SEL-10 protein comprising:

   a) determining conserved regions revealed by alignment of the wild-type SEL-10 or mutated SEL-10 protein sequences;

   b) synthesizing peptides corresponding to the revealed conserved regions;

   c) administering an amount of the synthesized peptides to a suitable animal effective to produce an antibody against the peptides in the animal; and

   d) testing the produced antibody for capability to bind wild-type SEL-10 or mutant SEL-10.

25. The method of claim 24, wherein the antibodies are produced by in vitro immunization.

26. The method of claim 24, wherein the produced antibody is tested by Western blot analysis.

27. The method of claim 24, wherein the produced antibody

is tested by immunoprecipitation.

28. The method of claim 24, wherein the produced antibody
    is tested by staining of cells or tissue sections.

29. An antibody capable of specifically binding to wild-
    type SEL-10 or mutated SEL-10.

30. An antibody produced by the method of claim 19 or 24.

31. The monoclonal antibody of claim 30.

32. A transgenic animal comprising the isolated nucleic
    molecule of claim 1, 2, 3, 4 or 5.

33. The transgenic animal of claim 32, wherein the animal
    is a *Caenorhabditis elegans*.

34. A transgenic animal comprising the isolated nucleic
    acid molecule of claim 2.

35. The transgenic animal of claim 34, wherein the animal
    is a *Caenorhabditis elegans*.

36. A method for identifying a compound which is capable
    of ameliorating Alzheimer's disease comprising
    administering an effective amount of the compound to
    the transgenic animal of claim 32, 33, 34 or 35,
    alteration of the conditions of the transgenic animal
    indicating that the compound is capable of
    ameliorating Alzheimer's disease.

37. A method for determining whether a compound is capable
    of ameliorating Alzheimer's disease comprising:

            a)    treating    *Caenorhabditis    elegans*
                  mutants having reduced, increased or
                  altered   sel-10   activity   with   the

-66-

compound; and

b)     determining   whether   the   compound
       suppresses, enhances or has no effect
       on the phenotype of the mutants, the
       suppression   or   enhancement   of   the
       phenotype indicating the compound is
       capable of ameliorating Alzheimer's
       disease.

38. A method for determining whether a compound is capable
of ameliorating Alzheimer's disease comprising:

a)     contacting the compound with a cell
       which expresses both SEL-12 and SEL-
       10; and

b)     determining   whether   the   compound
       increases, decreases or has no effect
       on the amount of SEL-12 in the cell,
       the increase or decrease of SEL-12
       indicating   that   the   compound   is
       capable of ameliorating Alzheimer's
       disease.

39. A method for determining whether a compound is capable
of ameliorating Alzheimer's disease comprising:

a)     contacting the compound with a cell
       which expresses both LIN-12 and SEL-
       10; and

b)     determining   whether   the   compound
       increases, decreases or has no effect
       on the amount of LIN-12 in the cell,
       the increase or decrease of LIN-12
       indicating   that   the   compound   is
       capable of ameliorating Alzheimer's

disease.

40. A method for determining whether a compound is capable
    of ameliorating Alzheimer's disease comprising:

        a)    contacting the compound with a cell
              which expresses both mammalian
              presenilin and SEL-10; and

        b)    determining whether the compound
              increases, or decreases or has no
              effect on the amount of mammalian
              presenilin in the cell, the increase
              or decrease of mammalian presenilin
              indicating that the compound is
              capable of ameliorating Alzheimer's
              disease.

41. A method for identifying a compound which is capable
    of treating cancer comprising administering an
    effective amount of the compound to the transgenic
    animal of claim 32, 33, 34 or 35, alteration of the
    conditions of the transgenic animal indicating that
    the compound is capable of treating cancer.

42. A method for determining whether a compound is capable
    of treating cancer comprising:

        a)    treating  *Caenorhabditis    elegans*
              mutants having reduced, increased or
              altered sel-10 activity with the
              compound; and

        b)    determining whether the compound
              suppresses, enhances or has no effect
              on the phenotype of the mutants, the
              suppression or enhancement of the
              phenotype indicating the compound is

-68-

capable of treating cancer.

43. A method for determining whether a compound is capable
of treating cancer comprising:

    a)    contacting the compound with a cell
which expresses both LIN-12 and SEL-
10; and

    b)    determining whether the compound
increases, decreases or has no effect
on the amount of LIN-12 in the cell,
the increase or decrease of LIN-12
indicating that the compound is
capable of treating cancer.

44. A method for determining whether a compound is capable
of treating cancer comprising:

    a)    contacting the compound with a cell
which expresses both SEL-12 and SEL-
10; and

    b)    determining whether the compound
increases, decreases or has no effect
on the amount of SEL-12 in the cell,
the increase or decrease of SEL-12
indicating that the compound is
capable of treating cancer.

45. A method for determining whether a compound is capable
of treating cancer comprising:

    a)    contacting the compound with a cell
which expresses both mammalian Notch
and SEL-10; and

    b)    determining whether the compound

-69-

increases, decreases or has no effect
on the amount of mammalian Notch in
the cell, the increase or decrease of
mammalian Notch indicating that the
compound is capable of treating
cancer.

46. A method for identifying a suppressor that affects
lin-12 or sel-12 activity in the same manner as sel-
10, comprising:

a)    mutagenizing mutant lin-12 or sel-12
      *Caenorhabditis elegans* worms with an
      effective amount of an appropriate
      mutagen:

b)    screening for revertants in the F1,
      F2, and F3 generations; and

c)    isolating the screened revertants,
      thereby identifying a suppressor of
      the phenotype of lin-12 or sel-12
      mutation.

47. A suppressor identified by the method of claim 46.

48. A method for identifying an enhancer that affects lin-
12 or sel-12 activity in the same manner as sel-10,
comprising:

a)    mutagenizing mutant lin-12 or sel-12
      *Caenorhabditis elegans* worms with an
      effective amount of an appropriate
      mutagen:

b)    screening for enhancement in the F1,
      F2, and F3 generations; and

-70-

c)  isolating the screened enhancers, thereby identifying an enhancer of the phenotype of lin-12 or sel-12 mutation.

49. An enhancer identified by the method of claim 48.

50. A method for producing suppressors of a sel-10 allele comprising:

a)  mutagenizing sel-10 mutant hermaphrodites with an effective amount of a mutagen;

b)  screening for revertants in the F1, F2, and F3 generations; and

c)  isolating the screened revertants.

51. A suppressor produced by the method of claim 50.

52. A method for identifying a suppressor gene comprising performing DNA sequence analysis of the suppressor of claim 51 to identify the suppressor gene.

53. The suppressor gene identified by the method of claim 52.

54. A method for producing enhancers of a sel-10 allele comprising:

a)  mutagenizing sel-10 mutant hermaphrodites with an effective amount of a mutagen;

b)  screening for enhanced mutants in the F1, F2, and F3 generations; and

-71-

c)      isolating the enhanced mutants.

55.     An enhancer produced by the method of claim 54.

56.     A method for identifying an enhancer gene comprising performing DNA sequence analysis of the enhancer of claim 55 to identify the enhancer gene.

57.     The enhancer gene identified by the method of claim 56.

58.     A method for reversing the malignant phenotype of cells comprising:

a)      linking the wild-type or mutated sel-10 gene to a regulatory element such that the expression of the sel-10 gene is under the control of the regulatory element; and

b)      introducing the linked sel-10 gene into the malignant cells for the expression of the sel-10 gene so as to reverse the malignant phenotype of cells.

59.     The method of claim 58, which further comprises placing the cells from step (b) in appropriate conditions to express the sel-10 gene such that the expression of the sel-10 gene will reverse the transforming phenotype of the malignant cells.

60.     The method of claim 59, which further comprises inducing the expression of the sel-10 gene which will reverse the transforming properties of the cells, thereby reversing the phenotype of the

-72-

malignant cells in the subject.

61.     A pharmaceutical composition comprising an
        effective amount of the compound identified by
        the method of claim 36 and a suitable carrier.

62.     A pharmaceutical composition comprising an
        effective amount of the compound identified by
        the method of claim 41 and a suitable carrier.

63.     A method of ameliorating Alzheimer's disease
        which comprises administrating the pharmaceutical
        composition of claim 61 in an amount effective to
        ameliorate Alzheimer's disease.

64.     A method of treating cancer which comprises
        administering the pharmaceutical composition of
        claim 62 in an amount effective to treat cancer.

# FIG. 1A  *sel-10* cloning



# FIG. 1B  Predicted *sel-10* transcription unit

## FIG. 2A

```
tcatagtttatcgactttcctttgtgttcaaattcttcattcctattcattccaattctttttcagccat


 M  W  P  R  N  D  V  H  M  D  D  G  S  M  T  P  E  D  Q  E  P  V  T  D  N  D  M  E  Y  N            30
ATGTGGCCACGAAATGATGTACACATGGATGATGATGGATCGATGACACCGGAGGAGCCAGGAGCCTGTTACCGATAATGATATGGAATATAAT    90


 D  N  G  E  E  S  S  Y  S  N  G  S  S  S  S  Y  N  A  D  K  L  S  S  S  R  P  L  Q  H  K            60
GACAATGGAGAGGAGTCGTACAGCAATGGCTCTTCTTCCAGCTACAATGCTGACAAATTATCGTCTTCCAGACCTTTGCAACACAAA          180


 L  D  L  S  A  S  P  S  R  N  N  D  L  N  P  R  V  E  H  L  I  A  L  F  K  D  L  S  S  A            90
CTTGATTTATCGGCTTCTCCCTCTCGAAACAACGACCTCAATCCGCGTGTGCAACATTGATCGCATTATTCAAGGATCATCAAGCGCG        270


 E  Q  M  D  A  F  T  R  L  L  Q  E  S  N  M  T  N  I  R  Q  L  R  A  I  I  E  P  H  F  Q           120
GAACAAATGGATGCATTCACACGTCTGCTTCAGGAATCCAACATGACAAATATTCGACAATTATTGAACCCCATTCCAG                  360


 R  D  F  L  S  C  L  P  V  E  L  G  M  K  I  L  H  N  L  T  G  Y  D  L  L  K  V  A  Q  V           150
CGTGATTTCCTCTGCCTCCCTGTCGAGCTCGGAATGAAATCCTTCACAATTAACCGGATATGACCTGCTCAAAGTGGCACAGGTG           450


 S  K  N  W  K  L  I  S  E  I  D  K  I  W  K  S  L  G  V  E  E  F  K  H  H  P  D  P  T  D           180
TCGAAAAATTGGAAATTGATATCTGAAATTGACAAAATTGGAAGAGTCTTGGGTGTCGAAGAGTTTAAACATCATCCAGATCCCACAGAC      540


 R  V  T  G  A  W  Q  G  T  A  I  A  A  G  V  T  I  P  D  H  I  Q  P  C  D  L  N  V  H  R           210
CGAGTTACTGGTGCGTGGCAAGGAACTGCAATTGCTGCTGGAGTCACTATTCCTGATCACATTCAGCCATGTGATCTTAAGTTCATCGA       630


 F  L  K  L  Q  K  F  G  D  I  F  E  R  A  A  D  K  S  R  Y  L  R  A  D  K  I  E  K  N  W           240
TTTCTAAAGTTGCAGAAGTTTGGAGATATCTTCGAACGCGCTGCTGACAAGTCACGTTATCTTCGAGCCGATAAAATTGAAAAGAACTGG      720
```

## FIG. 2B

```
                ↑                        I
N A N P I M G S A V L R G H E D H V I T C M Q I H D D Y L V                    270
AATGCGAATCCAATTATGGGTTCAGCAGTGCTACGCAGGACACGAAGATCATGTAATCACTTGTATGCAAATTCATGATGATGTCTTGGTG  810

                                                     II
T G S D D N T L K V W C I D K G E V M Y T L V G H T G G V W                    300
ACTGGATCTGACGATAACACTCTTAAAGTATGGTGTATTGACAAAGGAGAGGTTATGTACACACTGGTCGGCCACACTGGAGGAGTTTGG   900

                                    *
T S Q I S Q C G R Y I V S G S T D R T Y K V W S T V D G S L                    330
ACATCACAGATTTCTCAATGCGGAAGATATATTGTTAGCGGGTCCACTGATAGAACTGTAAAAGTTTGGAGTACTGTAGATGGTTCACTT   990

        III                                  ↑
L H T L Q G H T S T V R C M A M A G S I L V T G S R D T T L                    360
CTTCATACACTTCAAGGACATACTTCCACTGTTCGATGCATGGCTATGGCTGGTTCCATACTTGTCACTGATCACGAGATACCACTCTT  1080

                                        IV
R V W D V E S G R H L A T L H G H A A V R C V Q F D G T                        390
CGTGTATGGGACGTAGAATCCGGACGTCACCTGGCAACTTACATCATGGCCATCATGACGTTCAATTGATGGAACAACT            1170

                                                          V
V V S G G Y D F T Y K I W N A H T G R C I R T L T G H N N R                    420
GTTGTTTCGGGAGGATATGATTTTACCGTTAAAATTTGGAATGCTCATACTGGGAGATGCTCATACTCCTGACCGGTCATAACAATAGA 1260

V Y S L L F E S R S I V C S G S L D T S I R V W D F T R P                      450
GTTTATTCTCTTCTTTGAAAGCGAGCGATCGATCGTGTGCTCTGGCTCTCTGGACACTTCAATTCGCGTGTGGATTTTACACGACCG   1350
```

FIG. 2C

```
                     VI
E  G  Q  E  C  V  A  L  L  Q   G  H  T  S  L  T  S  G  M  Q  L  R  G  N  L  L  V  S  C  N    480
GAAGGCCAAGAATGTGTGGCTCTTTTGCAAGGACACACCTCACTTACATCCGGAATGCAACTTCGAGGCAATATTCTCGTGTCATGCAAT  1440
                                                                  VII
A  D  S  H  V  R  V  W  D  I  H  E  G  T  C  V  H  M  L  S   G  H  R  S  A  I  T  S  L  Q    510
GCAGATAGCCATGTTAGAGTATGGGATATTCACGAGGAACTGTGTACACATGCTTTCTGGACATCCGCTATCACTTCACTTCAA  1530
 *
W  F  G  R  N  M  V  A  T  S  S  D  D  G  T  Y  K  L  W  D   I  E  R  G  A  L  I  R  D  L    540
TGGTTTGGACGAAATATGGTAGCAACGAGTAGTGACGATGGAACTGTCAAATTGTGGGATATTGAGAGAGGTGCACTGATTCGAGATCTA  1620

V  T  L  D  S  G  G  N  G  G  C  I  W  R  L  C  S  T  S  T  M  L  A  C  A  V  G · S  R  N    570
GTAACTTTGGATTCTGGAGGCAATGGTGGCTGTATTTGGAGACTTTGTTCTACTTCTACGATGCTAGCGTGTGCAGTCGGATCTCGTAAC  1710

N  T  E  E  T  K  V  I  L  L  D  F  D  A  V  Y  P  *    587
AACACCGAGGAGACCAAAGTTATCCTTCTCGACTTTGATGCTGTATACCCTTAAcgaattctcgaatcctctgcccctgtacatagaatgt  1800
tcttgcttaggaactaatattgtacacgatgccctcattttaaatcaacaatgctcatcatgaatatagtcaaaagccaacagt
attgaaacgtcaaattgagaggaaaaacgaatttatgtgtctattcaactcgttatatcccgcccgccactaatttctcttttttta
ctattttttgtcagattctgtctcacactcttcttcctttatacaatagttcagtcagtatgtagtcctttatgtgacttctttt
ttattcaaatgatgggctcactactcccccagatttgattctcttatacaatagttcctttttttcgctttcatttttcgtttcttttt
tgatctaatgagcttttagtcccgtcggtccctctttttgtcttttatcgctttatgactatgcagacgctcattcgattaagtttac
cctcgacattgccttttttaaatttttgtcttcgtttatcgcagacgctcattgcgattaagtagttaataacaattattt
cataataaatatcgattcgtgtcatccgtctatatgtgattttctttt
```

FIG. 3A

Alignment of F-Box

SEL-10  127
CDC4    278
MD6      60

## FIG. 3B

Alignment of WD40 repeats

| | | | |
|---|---|---|---|
| I | SEL-10 | 253 | GHEDHVITCMIHDDVLVTGSDDNTLKVWC |
| | CDC4 | 419 | GHMTSVITCLQFEDNYVITGADDKMIRVYD |
| II | SEL-10 | 294 | GHIGGVWTSQISQCGRYIVSGSTDRTVKVWS |
| | CDC4 | 460 | GHDGGWALKYAHGG.ILVSGSTDRTVRVWD |
| III | SEL-10 | 336 | GHTSTVRCMAMAG....SILVTGSRDTTLRVWD |
| | CDC4 | 502 | GHNSTVRCLDIVEYKNIKYIVTSGRDNILHVWK |
| IV | SEL-10 | 376 | GHAAVRCVQFDGTTVVSGGYDFIVKIWN |
| | CDC4 | 569 | GHMASVRTVSGHGNIVVSGSYDNILIVWD |
| V | SEL-10 | 416 | GHNNRVYSLLFESERSIVCSGSLDTSLRVWD |
| | CDC4 | 609 | GHTDRIYSTIYDHERKRCISASMDTTIRIWD |
| VI | SEL-10 | 461 | GHTSLTSGMQLRGNILVSCNADSHVRVWD |
| | CDC4 | 671 | GHIALVGLLRLSDKFLVSAAADGSIRGWD |
| VII | SEL-10 | 501 | GHR...SAITSLQWFGRNMVATSSDDGTVKLWD |
| | CDC4 | 710 | HHTNLSAITT.FYVSDNILVSGSENQFN.IYN |

# FIG. 4A

## FIG. 4B

# FIG. 5

| A. CLASSIFICATION OF SUBJECT MATTER |
|---|
| IPC(6)  :C12P 21/06; C12N 1/20, 15/00; C07H 17/00 |
| US CL  :435/69.1, 320.1, 325, 252.3; 536/23.1, 23.5 |
| According to International Patent Classification (IPC) or to both national classification and IPC |

| B. FIELDS SEARCHED |
|---|
| Minimum documentation searched (classification system followed by classification symbols) |
| U.S.  :  435/69.1, 320.1, 325, 252.3; 536/23.1, 23.5 |

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

  APS, Dialog

| C. DOCUMENTS CONSIDERED TO BE RELEVANT |
|---|

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---|---|---|
| X<br>----<br>A | WILSON, R. et al. 2.2 Mb of contiguous nucleotide sequence from chromosome III of C. elegans. Nature. 03 March 1994, Vol. 368, pages 32-38, see entire document. | 1-7<br>----<br>8-14 |
| X<br>----<br>A | YOCHEM, J. et al. Structural comparison of the yeast cell division cycle gene CDC4 and a related pseudogene. J. Mol. Biol. 1987, Vol. 195, pages 233-245, see entire document. | 1, 6, 7<br>----------<br>2-5, 8-14 |

☐ Further documents are listed in the continuation of Box C.          ☐ See patent family annex.

| * | Special categories of cited documents: | "T" | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
|---|---|---|---|
| "A" | document defining the general state of the art which is not considered to be of particular relevance | | |
| "B" | earlier document published on or after the international filing date | "X" | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| "L" | document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | | |
| "O" | document referring to an oral disclosure, use, exhibition or other means | "Y" | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "P" | document published prior to the international filing date but later than the priority date claimed | "&" | document member of the same patent family |

| Date of the actual completion of the international search | Date of mailing of the international search report |
|---|---|
| 14 OCTOBER 1998 | 23 OCT 1998 |

| Name and mailing address of the ISA/US<br>Commissioner of Patents and Trademarks<br>Box PCT<br>Washington, D.C. 20231 | Authorized officer<br><br>KAREN COCHRANE CARLSON, PH.D. |
|---|---|
| Facsimile No.    (703) 305-3230 | Telephone No.    (703) 308-0196 |

Form PCT/ISA/210 (second sheet)(July 1992)★

# INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/15335

---

**Box I   Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
   because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
   because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

---

**Box II   Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

   **Please See Extra Sheet.**

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
   1-14

**Remark on Protest**   ☐ The additional search fees were accompanied by the applicant's protest.

   ☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1))(July 1992)★

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING
This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1.

Group I, claim(s) 1-14, drawn to nucleic acid encoding Sel-10.

Group II, claim(s) 15-18, drawn to Sel-10.

Group III, claim(s) 19-31, drawn to method of making antibodies with Sel-10.

Group IV, claim(s)32-35, drawn to transgenic animals.

Group V, claim(s) 37-40, drawn to method for identifying compounds for ameliorating Alzheimer's Disease.

Group VI, claim(s) 42-45, drawn to a method for identifying compounds capable of treating cancer.

Group VII, claim(s) 46, drawn to a method for identifying suppressors of lin12 or Sel-12.

Group VIII, claim(s) 47, drawn to suppressor of lin12 or sel-12.

Group IX, claim(s) 48, drawn to a method for identifying enhancers of lin12 or sel-12.

Group X, claim(s) 49, drawn to enhancers of lin12 or sel-12.

Group XI, claim(s) 50, drawn to a method for producing a suppressor of Sel-10.

Group XII, claim(s) 50, drawn to a suppressor of Sel-10.

Group XIII, claim(s) 52, drawn to a method for identifying a gene encoding a suppressor of Sel-10.

Group XIV, claim(s) 53, drawn to a gene encoding a suppressor of Sel-10.

Group XV, claim(s) 54, drawn to a method for producing an enhancer of Sel-10.

Group XVI, claim(s) 55, drawn to an enhancer of Sel-10.

Group XVII, claim(s) 56, drawn to a method for identifying a gene encoding an enhancer of Sel-10.

Group XVIII, claim(s) 57, drawn to a gene encoding an enhancer of Sel-10.

Group XIX, claim(s) 58-60, drawn to a method for reversing malignancy via antisense therapy.

The inventions listed as Groups I-XIX do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The products of Groups I, II, IV, VIII, X, XII, XIV, XVI, and XVIII differ in structure and function and therefore these products lack the same or corresponding special technical features.

The nucleic acid of Group I is not used in the methods of Groups III, V-VII, IX, XI, XIII, XV, XVII, or XIX. Therefore, Group I does not provide a special technical feature between Groups III, V-VII, IX, XI, XIII, XV, XVII, and XIX.